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Abstract 
HIV-1/HCV co-infection is a significant burden on global economy and public health. 
Highly active antiretroviral treatment (HAART) against HIV-1 is fairly effective. On the 
other hand, first generation direct acting antiviral drugs against HCV have improved cure 
rates but high cost and development of drug resistance are important concerns. Therefore 
PEGylated interferon (PEG-IFN) and ribavirin (RBV) are still essential components of anti-
HCV treatment, and identification of host factors that predict IFN/RBV treatment response is 
imperative. In my thesis research, we investigated the host genetic and immunological 
correlates of successful treatment response. We also investigated the mechanisms by which 
PEG-IFN is able to clear the virus (in responders). Impaired dendritic cell (DC) and T cell 
responses are associated with HCV persistence. It has been shown that IFN/RBV treatment 
enhances HCV-specific T cell functions and it is likely that functional restoration of DCs is 
the underlying cause. To test this hypothesis, we utilized an antibody cocktail (consisting of 
DC maturation, adhesion and other surface markers) to perform comprehensive phenotypic 
characterization of myeloid DCs (mDCs) and plasmacytoid DCs (pDCs) in a cohort of HIV-
1/HCV co-infected individuals undergoing IFN/RBV treatment. Our results showed that pre-
treatment frequencies of mDCs were lower in non-responders (NRs) compared to responders 
(SVRs) and healthy controls. The treatment was able to restore the frequency of mDCs in 
NRs, but it downregulated the frequency of CCR7+, CD54+ and CD62L+ mDCs. Pre-
treatment pDC frequencies were lower in NRs and decreased further upon treatment. NRs 
exhibited reduced frequency of CCR7+ pDCs and increased pDC PD-L1/CD86 ratio as a 
result of treatment. These findings demonstrate that functional state of DCs before/during 
therapy influences the treatment outcome. We also show that before treatment, PBMCs from 
  xvii 
SVRs secrete higher amounts of IFN-γ compared to controls and NRs. Upon genotyping 
IFNL3 polymorphisms rs12979860, rs4803217 and ss469415590, we found rs12979860 to 
be a better predictor of treatment outcome. Collectively, this part of the study led to 
identification of important correlates of IFN/RBV treatment response in patients. 
Next, we wanted to investigate how the expression of interferon-stimulated genes 
(ISGs) affects the treatment outcome. It is already known that high pre-treatment expression 
of ISGs in liver is a good predictor of poor response to IFN/RBV treatment, but there is no 
clear consensus regarding the correlation between ISGs expression in PBMCs and treatment 
outcome. We compared the expression of forty-six ISGs between NRs and SVRs both before 
and at week 4 of IFN/RBV treatment. We found that the pre-treatment levels of sixteen ISGs 
were moderately higher in SVRs compared to NRs. At week 4 of IFN/RBV treatment, 
nineteen ISGs were upregulated and fifteen ISGs were downregulated in SVRs. Next, we 
identified miRNAs whose expression can be regulated by IFN-Α in PBMCs. miR-155 was 
one of the many miRNAs upregulated by IFN-Α and its expression varied between NRs and 
SVRs both before and at week 4 of treatment. Overall, our results indicated that lower miR-
155 expression and higher levels of ISGs could be predictive of treatment success.  
Besides their well-appreciated role in direct antiviral defense, IFN-Α plays a critical 
role in the regulation of innate and adaptive immune response. Immunomodulatory properties 
of IFN-Α are facilitated by its action on DCs, professional antigen presenting cells critical to 
generation of protective immunity. Various microRNAs are known to regulate DC functions 
but it remains unclear whether IFN-Α exerts its effects on DCs through miRNAs. In this 
study, we examined miRNA expression patterns in myeloid and plasmacytoid DCs in 
response to IFN-α and observed miR-221 downregulation via IFN induced STAT3 inhibition 
  xviii 
in both. Using in silico approaches followed by experimental validation, BCL2L11, 
CDKN1C, and SOCS1 were identified as miR-221 targets. Moreover, miR-221 
overexpression in mDCs enhanced their secretion of proinflammatory cytokines IL-6 and 
TNF-α. In PBMCs isolated from HIV-1/HCV co-infected patients on standard IFN-α 
therapy, pre-treatment levels of miR-221 were significantly lower in non-responders 
compared to responders and healthy controls. Also, in patients PBMCs, miR-221 and 
CDKN1C, CD54, IL-6 and TNF-α levels correlated similarly as observed earlier in mDCs. 
In addition, we isolated total liver cells and kupffer cells (antigen presenting cells in liver) 
from HCV infected individuals as well as individuals with alcoholic cirrhosis. We found that 
both total liver cells and kupffer cells from HCV-infected individuals had significantly higher 
miR-221 levels compared to cirrhotic patients which might indicate HCV-mediated 
impairment in IFN signaling. Overall, this part of our study demonstrated the role of IFN-
α/miR-221 axis in HCV pathogenesis and response to IFN-based treatments. 
Collectively, during my thesis research, we were able to demonstrate the correlation 
between miR-221 and miR-155 expression in PBMCs and response to PEG-IFN/RBV 
treatment. We were also able to characterize the DC phenotype and ISGs expression (in 
PBMCs) of NRs and SVRs both before and during the treatment. We are confident that this 
work will prove to be beneficial for both diagnostic purposes and for understanding of the 
role of DCs in HCV pathogenesis.  
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Background and significance 
Co-infection with human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) is 
a significant health problem with about five million HIV-1/HCV co-infected individuals 
worldwide. Antiretroviral treatment (ART) has proven very successful in controlling HIV-1 
infection in both HIV-1 mono-infected and HIV-1/HCV co-infected individuals. On the other 
hand, administration of anti-HCV direct acting antiviral agents (DAAs) alone or in combination 
with PEGylated-Interferon-α/Ribavirin (IFN/RBV) has improved cure rates but high cost and 
development of drug resistance are important concerns. Therefore IFN/RBV combination 
therapy still remains an important therapeutic intervention against HCV, however its low success 
rate (~50%) and side effects necessitates a thorough understanding of host genetic and 
immunological factors that help predict the outcome of IFN/RBV therapy with accuracy. The 
complete mechanism of action of IFN/RBV therapy is not understood. IFN-α is a pleiotropic 
cytokine with potent antiviral, antiproliferative and immunomodulatory properties. It has been 
shown that IFN/RBV treatment enhances HCV-specific T cell functions and it is possible that 
augmentation of DC functions is the underlying cause. In light of potential mechanisms by which 
IFN-α can exert its biological effects on target cells, it has been shown that IFN-α can regulate 
the expression of miRNAs, which mediate its immunomodulatory effects. However, the IFN-α-
miRNA axis and its role in DC functions, has not been investigated. Overall goal of our study is 
to understand the immunomodulatory effects of IFN-α on DCs and whether that plays a role in 
differential outcome of IFN/RBV treatment. Answering this basic question may bring us a step 
closer to answering a fundamental question, which is why IFN-α effectively controls the 
development of some immunopathologies while exacerbating the severity of others.  
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Chronic HIV-1 infection 
HIV-1 was the result of several independent zoonotic transmissions of simian immunodeficiency 
viruses during twentieth century1-3. HIV-1 (120 nm in diameter) belongs to genus lentivirus of 
retroviridae family of enveloped viruses. HIV infection occurs through contaminated blood, 
semen, vaginal fluid, pre-ejaculate or breast milk. HIV-1 primarily infects CD4 helper T-cells 
however there is evidence that it can infect macrophages and DCs as well3-16. HIV-1 infection 
leads to a decline in CD4+ T cells through a number of mechanisms, including direct viral killing 
of infected cells, apoptosis of uninfected bystander cells, and killing of infected CD4+ T cells by 
CD8+ cytotoxic lymphocytes. Severe reduction in CD4 T-cell levels leads to acquired 
immunodeficiency syndrome characterized by severe immunosuppression that allows life-
threatening opportunistic infections and cancers to thrive17,18. According to a recent report by the 
Joint United Nations Programme on HIV/AIDS, an estimated 33.4 million people around the 
world are living with HIV infection.19 Centers for Disease Control and Prevention (CDC) 
estimated that 1,178,350 persons aged 13 and older were living with HIV-1 infection in the 
United States as of 200820. In 2009, there were an estimated 48,100 new HIV infections21.  
 
HIV-1 life cycle 
HIV-1 is composed of two copies of positive single-stranded RNA that codes for nine genes 
(gag, pol, and env, tat, rev, nef, vif, vpr, vpu, and sometimes a tenth tev, which is a fusion of tat 
env and rev), encoding 19 proteins. Viral RNA is enclosed within a capsid composed of a viral 
protein p24. RNA is tightly bound to nucleocapsid proteins, p7, and enzymes such as reverse 
transcriptase, proteases, ribonuclease and integrase that play important roles in viral life cycle 
(Fig. 1.1). A matrix composed of the viral protein p17 surrounds the capsid ensuring the integrity 
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of the virion. This is, in turn, surrounded by the viral envelope that is composed of two layers of 
phospholipids derived from the cell membrane of previously infected cell at the time of viral 
budding. HIV-1 envelope spikes are comprised of trimers of non-covalently linked gp120 
(surface glycoprotein) and gp41 (transmembrane glycoprotein) heterodimers22,23. Initial 
interaction between gp120 and CD4 (Main HIV-1 entry receptor) on the surface of CD4 T-cells 
induces conformational changes in gp120 that exposes binding site for a second cell surface 
molecule (Co-receptor), typically CC-chemokine receptor 5 (CCR5)24,25. Engagement of this co-
receptor leads to insertion of fusion peptide, located at the N-terminus of gp41, into the target 
cell plasma membrane. This event triggers significant rearrangements of trimerized N- and C-
terminal repeat sequences within gp41 followed by formation of a six-helix hairpin structure, 
apposition and fusion of viral and host cell membranes26 resulting in entry of HIV-1 into the cell. 
The HIV core houses reverse transcriptase (RT), integrase (IN) and viral genomic RNA, and is 
encased by a cone-shaped shell composed of viral capsid (CA) proteins. Partial core shell 
uncoating facilitates reverse transcription of viral genomic RNA to cDNA. Following reverse 
transcription, pre-integration complex (PIC) is assembled and imported into the nucleus. Inside 
nucleus, PIC-associated integrase orchestrates the formation of the integrated provirus, aided by 
host chromatin-binding protein lens epithelium-derived growth factor (LEDGF). Proviral 
transcription, mediated by host RNA polymerase II (RNA Pol II) and positive transcription 
elongation factor b (P-TEFb), yields viral mRNAs. These mRNAs after getting exported outside 
the nucleus (via host protein Exportin 1), serve as templates for translation of viral proteins. In 
the end, HIV-1 proteins along with HIV-1 RNA form viral particles and bud out of the cell by 
utilizing ESCRT (endosomal sorting complex required for transport) complexes and ALIX and is 
accompanied by protease-mediated maturation to create infectious viral particle. 
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 Figure 1.1: HIV-1 life cycle (Engelman et al, Nature Reviews Microbiology, 2012). The 
infection begins when the envelope (Env) glycoprotein spikes engage the receptor CD4 and the 
membrane-spanning CCR5 co-receptor, leading to fusion of the viral and cellular membranes 
and entry of the viral particle into the cell. The HIV core which houses reverse transcriptase 
(RT), integrase (IN) and viral genomic RNA, is encased by a cone-shaped shell composed of 
viral capsid (CA) proteins. Partial core shell uncoating facilitates reverse transcription of viral 
genomic RNA to cDNA. Following reverse transcription, pre-integration complex (PIC) is 
assembled and imported into the nucleus. Inside nucleus, PIC-associated integrase orchestrates 
the formation of the integrated provirus, aided by host chromatin-binding protein lens 
epithelium-derived growth factor (LEDGF). Proviral transcription, mediated by host RNA 
polymerase II (RNA Pol II) and positive transcription elongation factor b (P-TEFb), yields viral 
mRNAs. These mRNAs after getting exported outside the nucleus (via host protein Exportin 1), 
serve as templates for translation of viral proteins. In the end, HIV-1 proteins along with HIV-1 
RNA form viral particles and bud out of the cell by utilizing ESCRT (endosomal sorting 
complex required for transport) complexes and ALIX and is accompanied or soon followed by 
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Treatment of HIV-1 infection 
The first effective treatment against HIV-1 involved the use of nucleoside reverse transcriptase 
inhibitor (NRTI) zidovudine (AZT) in 198727. Subsequently several more NRTIs were developed 
but were unable to suppress HIV-1 for long periods of time and patients eventually succumbed to 
infection28. In 1996, indinavir belonging to a new class of antiviral agents, protease inhibitors 
began to be used in combination with two NRTIs and showed 60% to 80% decline in rates of 
AIDS progression and death29-31. There are several classes of drugs, which are usually used in 
combination, to treat HIV infection. Use of these drugs in combination is termed as highly active 
anti-retroviral therapy (HAART). Anti-HIV-1 drugs are broadly classified by the phase viral life 
cycle that the drug inhibits. Typical combinations include two NRTIs along with one drug 
belonging to the class of non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease 
inhibitors (PIs) or integrase nuclear strand transfer inhibitors (INSTIs). Other classes of 
inhibitors are indicated in fig. 1.1. Post HAART, clinical management of HIV-1 has become very 
effective, although there are some studies that show that despite effective suppression of HIV-1 
and restoration of CD4 numbers to normal levels, the immune system fails to recover fully. This 
may affect a person’s ability to mount an effective immune response against future infections 
with various pathogens. 
 
Chronic HCV infection 
HCV was discovered in 198932 and was found to be the major cause of non-A, non-B post-
transfusion hepatitis33. Soon it led to development of nucleic acid–based diagnostics for blood 
product screening34. HCV is a small (55–65 nm in size) 9.6-kb single-stranded, positive-sense, 
enveloped RNA virus belonging to genus hepacivirus in the flaviviridae family of enveloped 
7
   Dissertation: Mohit Sehgal 
 
Chapter 1 
   
viruses. HCV is transmitted primarily through large or repeated percutaneous (i.e., passage 
through the skin) exposures to infectious blood such as during injection drug use (currently the 
most common means of HCV transmission in United States). HCV mainly infects hepatocytes, 
however there is evidence that HCV can replicate in PBMCs and various B and T-cell lines35-39 
as well as DCs40. Chronic HCV infection is a major cause of chronic hepatitis, liver cirrhosis and 
hepatocellular carcinoma (HCC) worldwide. Based on genetic differences between HCV 
isolates, HCV is classified into seven genotypes (1–7) with several subtypes within each 
genotype (represented by lower-cased letters). Genotypes differ by 30–35% of the nucleotide 
sites over the complete genome. The difference in genomic composition of subtypes of a 
genotype is usually 20–25%. Most common HCV genotypes are 1a and 1b, which cause 60% of 
global HCV infections. HCV infects humans and chimpanzees. Availability of chimpanzee 
models of HCV41 has been crucial in studies of HCV immunity and pathogenesis. In addition, 
genetically modified HCV-permissive mice have also been developed42. According to the latest 
update by the World Health Organization (WHO), about 170 million people are chronically 
infected with HCV and more than 350,000 people worldwide die from HCV-related liver disease 
each year43. Acute HCV infection is characterized by appearance of HCV RNA in serum, 
followed by elevation in alanine aminotransferase (ALT) levels. Anti-HCV antibodies appear 
late. The majority of acutely infected patients are asymptomatic. Approximately 10% to 15% of 
asymptomatic patients clear the virus spontaneously. Symptomatic patients or patients who were 
asymptomatic but got diagnosed with HCV infection are given a weekly dose of PEG-IFNα2a or 
PEG-IFNα2b and a daily dose of ribavirin for 24 to 48 weeks. This treatment clears HCV in 
approximately 50% of patients and the remaining develop chronic infection, which leads to many 
liver disorders such as cirrhosis and hepatocellular carcinoma (HCC). 
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HCV life cycle 
HCV entry into its target cells is a multi-step process (Fig. 1.2A) Interaction between HCV 
envelope glycoproteins E1-E2 and glycosaminoglycans (GAGs) expressed on the surface of 
target cells is an important first step in viral entry. HCV circulates in various forms in the 
infected host and can be associated with low-density lipoproteins (LDL) and very-low-density 
lipoproteins (VLDL), both of which represent the infectious fraction of HCV. Therefore LDL 
receptor (LDLR) has also been proposed to participate in initial HCV capture. Upon initial 
binding of HCV to target cell surface, scavenger receptor BI (SR-BI), CD81 tetraspanin and tight 
junction proteins Claudin-1 (CLDN-1) and Occludin (OCLN) contribute to HCV uptake via 
clathrin-mediated endocytosis44,45. CLDN6 and CLDN9 can replace the function of CLDN1 in 
HCV entry, but they are expressed only at low levels in the liver46. HCV containing endosomes 
undergo acidification, which induces conformational changes in HCV glycoproteins, leading to 
fusion of viral and endosomal membranes and subsequent uncoating. Some studies suggest that 
in addition to infection with cell-free virus, direct cell-to-cell transmission occurs in the liver, 
which may explain the ability of HCV to avoid neutralization by HCV neutralizing antibodies. 
However, most HCV entry factors overlap between the two routes. After uncoating, HCV RNA 
released into the cytoplasm is translated via an internal ribosome entry site29 located in the 5’ 
non-coding region of the genome47. RNA translation occurs at the rough endoplasmic reticulum 
(ER) giving rise to a single ~3,000 amino-acid polyprotein, which is processed by cellular and 
viral proteases into at least 10 different protein products (Fig. 1.2B). These products include the 
structural proteins core, E1 and E2 and nonstructural proteins p7, NS3, NS4A, NS4B, NS5A and 
NS5B47. The structural proteins and the p7 polypeptide are processed by the endoplasmic 
reticulum (ER) signal peptidase whereas remaining non-structural proteins are processed by two 
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viral proteases, the NS2–3 protease and the NS3–4A serine protease. The core protein interacts 
with viral RNA and constitutes the nucleocapsid. E1 and E2 are envelope glycoproteins that 
form non-covalent heterodimeric complex E1-E2. E1-E2 is necessary for viral binding and 
subsequent entry into target cells (discussed above).  It might also play an important role in 
subcellular localization of virion components as well as viral assembly. Glycosylation and 
folding of E1 and E2 is a complex process that involves ER chaperone machinery. The 
transmembrane domains of E1 and E2 (located at their C-termini) are involved in 
heterodimerization and retention of E1 and E2 in ER47. The nonstructural proteins encode 
enzymes or co-factors that catalyze and regulate HCV replication. Processing of HCV 
nonstructural polypeptide is catalyzed by two virally encoded proteases. NS2-NS3 is a zinc-
dependent metalloproteinase that undergoes autocatalytic cleavage to produce NS2 and NS3. 
NS3 is a serine protease that catalyzes the cleavage of remaining nonstructural polypeptide to 
produce NS4A, NS4B, NS5A and NS5B, which, together with NS3 and (possibly) host cellular 
proteins, form the HCV replication complex or ‘Replicase’. NS3 protein also contains a 
superfamily 2 DExH/D-box helicase domain that is capable of nucleic-acid binding and 3′ to 5′ 
translocation coupled to ATP hydrolysis4878. Although its exact role is unknown, this activity 
could be important for separation of nascent and template RNA strands, unwinding of local RNA 
secondary structures or displacement of RNA-binding proteins. The NS4A protein has two 
known functions: 1) to form a stable complex with NS3 to facilitate the membrane localization 
of the NS3-NS4A complex in the ER, and 2) to act as a cofactor for NS3 protease. Interestingly, 
the NS3-NS4A serine protease is known to cleave mitochondrial antiviral signaling protein 
(MAVS) and Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) adaptor 
proteins, resulting in blockade of IFN synthesis mediated by retinoic acid–inducible gene-I 
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(RIG-I) and Toll-like receptor 3 receptors respectively49. Inhibiting NS3-NS4A is thus an 
attractive strategy to control HCV. NS3-NS4A protease inhibitors telaprevir and boceprevir were 
the first DAAs approved to be used in combination with PEG-IFN/RBV for treatment of HCV 
genotype 1 infection. NS4B is a relatively poorly characterized protein. One of its functions is to 
induce the formation of the membranous web that serves as a scaffold for replicase. NS4B might 
also have a role in regulation of NS5A hyperphosphorylation. The NS5A is a phosphoprotein 
that is implicated in mediating HCV resistance to IFN therapy as well as regulation of viral 
replication through its interaction with NS5B, which is RNA-dependent RNA polymerase 
(RdRp) that catalyzes the replication of HCV RNA50. The replicase is assembled at the ER 
membrane, where viral RNA replication takes place. Positive-stranded viral RNA genome serves 
as a template for the synthesis of a single, negative-stranded RNA. These two RNA strands 
remain base-paired and NS5B copies the resulting double-stranded RNA molecule by semi-
conservative replication to generate multiple copies of positive-stranded viral RNA genomes51-53. 
Importantly, the double-stranded RNA intermediate is one of the pathogen-associated molecular 
patterns recognized by the innate immune system. Importantly, NS5B lacks a proofreading 
function and is, therefore, highly error-prone. Lack of proofreading function results in generation 
of many HCV genetic variants (referred to as quasispecies) within the same individual. This 
genetic diversity provides an ideal pool from which genetic variants that are adapted to the 
antiviral effects of anti-HCV drugs are selected and thus lead to development of drug resistance. 
The progeny HCV RNA associates with core protein to form the nucleocapsid. The nucleocapsid 
is enveloped by budding into ER lumen. Finally, infectious virions are transported to the plasma 
membrane (via golgi complex) and released outside the cell50 
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Treatment of HCV infection 
Since its first use in 1986, recombinant IFN-α has continued to be a major component of anti-
HCV treatment regimen. In the beginning, use of IFN-α alone had very low (~20%) rate of 
success which is defined as persistent absence of serum HCV RNA for 6 months or longer after 
therapy (sustained virological response). Also, use of IFN-α was (still is) toxic and had 
significant side effects, such as anemia, thrombocytopenia, neutropenia, diarrhea, and flulike 
symptoms such as fever, chills, fatigue, headache, and muscle aches. Treatment success has 
shown a stepwise improvement following the introduction of ribavirin (in 1995) and PEGylation 
of IFN-α (in 2001). In 1996, the first three-dimensional structure of HCV genotype 1 serine 
protease (NS3) was published and fuelled the development of drugs that could inhibit NS3. In 
2011, two NS3 inhibitors, Telaprevir (Vertex Pharmaceuticals) and Boceprevir (Merck), were 
approved by FDA to be used in combination with PEG-IFN/RBV in order to treat HCV genotype 
1 infection. In 2014, a nucleotide analog RNA polymerase inhibitor, Sofosbuvir (Gilead 
Sciences, Inc.)  was approved to treat infection with all HCV genotypes. These direct acting anti-
HCV drugs have improved cure rates, however development of drug-resistant HCV variants, 
drug toxicity and high cost of these drugs remain important concerns. Also, these drugs have 
better efficacy when used in combination with IFN/RBV. Therefore, IFN and RBV still continue 
to be important components of anti-HCV treatment regimen. A new generation of anti-HCV 
drugs will probably improve response rates and might completely replace IFNs in chronic HCV 
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Figure 1.2: (A) HCV lifecycle (Pereira et al, Nature Reviews Gastroenterology and 
Hepatology, 2009). Extracellular HCV virions interact with receptor molecules at the cell 
surface and undergo clathrin-mediated endocytosis. Following HCV glycoprotein-mediated 
membrane fusion, HCV nucleocapsid (containing viral RNA) is released into cytoplasm. 
Genomic RNA is translated into a single polyprotein that is processed into mature HCV proteins. 
The endoplasmic reticulum (ER) is modified by viral and cellular factors to form a membranous 
web, which is the major site of viral RNA amplification. Six of the mature HCV proteins assist 
the replication of viral RNA via synthesis of positive strands (+) from a replicative intermediate 
negative RNA strand (-) template. A portion of this newly synthesized RNA is packaged into 
nucleocapsid and associated with HCV glycoproteins, a process that leads to virion budding into 
ER. During processing through the cellular secretory pathway the virions achieve maturation. 
Mature virions are released from the cell  
(B) Genetic organization and polyprotein processing of HCV (Scheel et al, Nature 
Medicine, 2013). HCV RNA genome consists of a single open-reading frame flanked by 5′ and 
3′ untranslated regions (UTRs). Binding of miR-122 to 5′ UTR is known to stabilize HCV RNA. 
Internal ribosome entry site 29-mediated translation yields a polyprotein that is processed into 
mature structural and non-structural (NS) proteins. Core protein is cleaved by cellular signal 
peptide peptidase (white triangle) after cleavage from E1 by the cellular signal peptidase, which 
also cleaves E1, E2 and p7 from the polyprotein (gray triangles). NS2-NS3 protease cleaves 
itself (red triangle). The NS3 protease located in the first one-third of NS3, assisted by its 
membrane-bound cofactor, NS4A, cleaves the remaining proteins NS3, NS4A, NS4B, NS5A and 
NS5B (green triangles). Glycosylation of E1 and E2 (black dots) and the functions of the 
individual HCV proteins are indicated. 
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Chronic HIV-1/HCV co-infection 
Apart from HIV-1 and HCV-monoinfected patients, a significant population (~ five million co-
infected individuals worldwide) of HIV-1/HCV co-infected patients exists. Overall, co-infection 
with HCV is found in 30% of HIV-infected patients and in 60% to 90% of HIV-infected 
injection drug users.54-56 A weak and narrowly focused antiviral T-cell response is a common 
denominator in both these chronic viral infections. HIV-1/HCV co-infection is associated with 
accelerated progression to hepatic fibrosis and higher rates of liver decompensation and death 
compared to HCV monoinfection. Liver disease is a leading cause of non-AIDS-related mortality 
among HIV-infected patients. Recent studies have revealed multiple mechanisms by which HIV-
1 and HCV lead to accelerated disease progression. HIV-1 infection increases HCV replication, 
augments HCV-induced hepatic inflammation, increases hepatocyte apoptosis, increases 
microbial translocation from the gut and leads to an impairment of HCV-specific immune 
responses. IFN/RBV has been less successful in co-infected individuals compared with HCV-
monoinfected patients. With multiple direct-acting antiviral agents in development to treat HCV, 
a unique opportunity exists to redefine the treatment paradigm for co-infected patients, which 
incorporates data on fibrosis stage as well as potential drug interactions with antiretroviral 
therapy.  
 
Immunobiology of dendritic cells 
Dendritic cells (DCs) are a specialized category of professional antigen-presenting cells (APCs) 
that act as messengers between the innate and the adaptive immune system57. Immature DCs are 
derived from hematopoietic bone marrow progenitor cells and are widely distributed within 
tissues such as skin, mucosal surfaces, and blood that come in direct contact with the external 
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environment. DCs are equipped with pattern recognition receptors (PRRs) such as Toll-like 
receptors (TLRs), whose role is to sense a wide array of pathogen-associated molecular patterns 
(PAMPs). TLRs can either be present on DC surface or on specialized intracellular 
compartments called endosomes. In humans, the TLR family consists of 10 members are present 
(named TLR 1–10) and each member is specific for the PAMP it recognizes; TLR7, for example, 
recognizes single-stranded RNA and TLR3 recognizes double-stranded RNA57. In humans, 
plasmacytoid DCs (pDCs) express TLR7 and TLR9, whereas myeloid DCs (mDCs) express 
TLR1, TLR2, TLR3, and TLR8 (reviewed here58). Upon TLR-mediated viral sensing and 
processing, DCs get activated and migrate to lymph nodes where they prime a naive T cell 
against the viral peptide that is presented on their surface. 
DCs process extracellular antigens via the lysosomal pathway and present the resulting 
peptides on major histocompatibility complex (MHC) class II molecules. In addition, they can 
process, via the proteasomal pathway, the intracellular proteins that are either produced by the 
virus during direct infection of DCs or enter DCs during cross-presentation (the cell biology of 
antigen processing is reviewed here59). After viral processing, DCs become activated and 
migrate, via blood or lymph, to the draining lymph nodes, where they transform into mature DCs 
in the T-cell-rich areas. Maturation of DCs involves morphological changes such as dendrite 
formation, cytoskeleton reorganization, redistribution of MHC molecules from intracellular 
endocytic compartments to the surface, inhibition of antigen uptake, and increase in the surface 
expression of co-stimulatory molecules (such as CD80 and CD86), adhesion molecules (e.g., 
CD54), and chemokine receptors (such as CXCR4 and CCR7) (reviewed here60). DCs exhibit 
heterogeneity at several levels, including function, phenotype, and anatomical location61. DCs in  
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epidermis are referred to as Langerhans cells (LCs); dermal DCs are found in dermis; and 
interstitial DCs are found in all peripheral tissues except skin. Blood DCs are broadly classified 
into two major groups: mDCs and pDCs. mDCs further comprise different subsets. Table 1 
summarizes the phenotype and functional characteristics of various DC subsets found in blood. 
Different DC subsets have acquired both distinct and overlapping roles in the immune system. 
Both mDCs and pDCs provide a critical link between innate and adaptive immune response 
against the virus62. Fig.1.3 illustrates the role of DCs in initiating and regulating the adaptive 
immune response. Activated mDCs are responsible for priming CD4+ and CD8+ T cells against a 
specific pathogenic epitope. In addition to that, they produce interleukin (IL)-12 and IL-15, both 
of which activate natural killer (NK) cells as well as promote the differentiation of epitope-
specific CD4+ T-helper (TH) cells and CD8
+ T cells into TH1 cells and cytotoxic T lymphocytes 
(CTLs) respectively. Activated NK cells have two major roles: one is to secrete interferon-γ 
(IFNγ), which inhibits viral replication in infected cells, and second is to kill the virus-infected 
cells directly through the release of cytolytic mediators such as granzyme. TH1 cells also secrete 
IFNγ, which stimulates the activation of CTLs and the production of neutralizing 
immunoglobulin G2a antibodies against the viruses by plasma cells. In contrast to mDCs, whose 
main role is to prime T-cells against the virus, pDCs function as one of the earliest mediators of 
antiviral immune response by producing large amounts of type I IFNs (IFNα and IFNβ) upon 
viral sensing. Besides inducing an antiviral state in virus-infected cells, type I IFNs take part in 
activation of NK cells 63 and promotion of CD4+ and CD8+ T-cell differentiation and survival.64 
In addition, pDCs have also been shown to act as APCs.65-67Interestingly, recent data also 
suggests that pDCs can facilitate CD4+ TH cell responses to persistent viruses independently of 
direct antigen presentation68,69, making it necessary to learn more about the role of pDCs in 
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antiviral immune response. The importance of DCs in resolving viral infection has been shown 
for several viruses, such as human respiratory syncytial virus and influenza virus70,71. Our lab has 
published several studies about the role of DCs in HTLV-1, HIV-1, and HCV infection72-84. 
 
HIV-1 and HCV can infect DCs 
The presence of DCs in the skin and blood as well as at the mucosal surfaces, and the proficiency 
of DCs in antigen uptake, predisposes them to be the primary targets for viruses. Therefore it is 
possible that HIV-1 and HCV infect DCs. Replication of the viral genome along with the 
expression of viral proteins in DCs might interfere with many signaling pathways in DCs, 
leading to impairment of DC functions and thus rendering them incapable of stimulating a proper 
T-cell response against the virus. For example, ICP47 of herpes simplex virus 1 and US6 of 
human herpes virus 5 are known to inhibit the loading of antigenic peptides onto MHC class I 
molecules, leading to reduced ability of infected DCs to prime naïve T cells efficiently.85 
The main target cells for HIV-1 are mononuclear leukocytes bearing CD4 and the 
CCR5/CXCR436,86-89, but LCs, pDCs, and mDCs have also been reported to be susceptible to 
HIV-1 infection.4-16However, HIV-1 replication is generally less productive in DCs than in CD4+ 
T cells4,12,14,90-92, and the frequency of HIV-1-infected DCs in the blood has been reported to be 
10 to 100 times lower than that of CD4+ T cells.93In vitro experiments in which blood DCs from  
uninfected donors were incubated with primary HIV-1 followed by intracellular staining of HIV-
1 capsid protein, p2416, demonstrated that virus can productively infect 1-3% of blood DCs. 
Immature DCs are more susceptible to HIV-1 infection than mature DCs94, perhaps partly as a 
result of their higher antigen uptake capacity. Interestingly, replication of HIV-1 in pDCs was 
found to increase substantially following CD40 ligation95. CD40 is a co-stimulatory protein 
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found on APCs and its binding to CD40 ligand (CD40L) on TH cells activates APCs to perform a 
variety of functions. Thus, HIV-1 replication in pDCs may be upregulated through its interaction 
with activated CD4+ TH cells in extrafollicular zones of lymphoid tissue, pointing towards their 
role as HIV-1 reservoirs. 
HCV primarily infects and replicates in hepatocytes; however, evidence is accumulating 
about extrahepatic replication of HCV, especially in PBMCs. The highly conserved 
5′untranslated region of HCV RNA has been shown to vary between PBMCs and plasma in the 
same individual37,96, suggesting that HCV alters its replication inside non-hepatic cells. 
Lymphoid cells may act as HCV reservoirs thus helping in establishment of chronic infection. 
Different studies have shown the presence of low levels of HCV RNA in serum and lymphoid 
cells after spontaneous or IFN/RBV-induced resolution of chronic hepatitis C.97,98 In patients 
with sustained virological response, small quantities of HCV RNA have been shown to persist in 
liver or in PBMCs for up to 9 years.98 HCV may persist and replicate in the liver and PBMCs of 
healthy, anti-HCV antibody positive, serum HCV RNA-negative patients who have persistently 
normal alanine aminotransferase levels.99 This could present a potential risk for reactivation, 
especially in case of immunosuppression caused due to the presence of HIV-1 infection in the 
same individual. In fact, HCV RNA in peripheral blood cell subsets in HIV/HCV co-infected 
patients at the end of IFN/RBV treatment is associated with virological relapse100. Interestingly, 
HCV RNA was shown to reemerge in apparent sustained virological responders receiving 
immune suppressive therapy101,102. This proved that HCV persists years after IFN/RBV-induced 
resolution from plasma, and continued immune surveillance is required to prevent its recurrence 
even in sustained virological responders.101 As far as DCs are concerned, HCV genomic RNA  
20
   Dissertation: Mohit Sehgal 
 
Chapter 1 
   
Figure 1.3: Role of DCs in antiviral immune response. Following viral antigen uptake, mDCs 
and pDCs become activated and migrate to lymphoid tissue where they prime naïve CD4+ T cells 
and CD8+ T cells. In addition, they produce a range of cytokines, such as IFN-α, IL-12, and IL-
15, which are responsible for activating NK cells and influence T-cell survival and 
differentiation. Depending on the cytokine signal, CD4+ T cells differentiate into TH1 or TH2 
cells (dashed arrows). TH1 cell-mediated IFNγ secretion stimulates the activation of CTLs and 
the production of immunoglobulin G2a antibodies by B cells. TH2 cell-mediated cytokine 
production simulates immunoglobulin G1 antibody production by B cells but also inhibits 
activation of TH1 cells. Virus-specific antibodies can neutralize the virus and thus help in viral 
containment and resolution. NK cells and CTLs inhibit viral replication through the secretion of 
IFNγ or through the lysis of virus-infected cells by releasing cytolytic mediators (such as 
perforin and granzymes). In addition, pDCs are characterized by their ability to produce large 
amounts of type I IFNs in response to many viruses. Type I IFNs not only inhibit viral 
replication but also enhance NK cell–mediated cytotoxicity. Boxes have the same shade as the 
cell that produces the cytokine. The arrows indicate the effect of HIV-1 and HCV on the 
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has been detected in mDCs and pDCs isolated from the blood of HCV-infected patients40,103. 
One study, which used strand-specific semi quantitative reverse transcription polymerase chain  
reaction, has shown that three out of twenty four HCV-infected patients had DCs carrying the 
replicative intermediate of HCV.40 More such studies are needed to clearly establish whether 
HCV replicates in blood DCs of infected patients. In one study, monocyte-derived DCs 
(MDDCs) from healthy donors were found to contain HCV replicative intermediate when 
incubated with the serum of HCV-infected patients.104 This study provides evidence that DCs 
can at least support the first steps of viral life cycle. However, other studies wherein MDDCs and 
various blood DC subsets were incubated with infectious recombinant HCV were not successful 
in detecting viral replication or viral protein synthesis.105-107 
In summary, DCs can support HIV-1 replication, although at a level much lower than 
CD4+ cells (primary targets for HIV-1), but they cannot support the production of HCV virions, 
even though HCV may be able to infect DCs and initiate its replication. Many explanations are 
possible: 1) as professional APCs, DCs might degrade the virus in intracellular compartments 
before it completes its replicative cycle. DC-specific ICAM-3 (intercellular adhesion molecule-
3) grabbing non-integrin (DC-SIGN or CD209) is a C-type lectin receptor (CLR)108,109 that has 
been shown to promote uptake and presentation of HIV-1 by MHC class I and class II 
molecules.110 Scavenger receptor class B member 1 (SRB1) has been shown to mediate in HCV 
uptake and presentation111; 2) Host factors required for HIV-1 and HCV replication might be 
missing in DCs, or DC-specific host factors might restrict HIV-1 and HCV replication. For 
example, cellular factors such as cytidine deaminase APOBEC3G (apolipoprotein-B mRNA-
editing enzyme, catalytic polypeptide-like 3G)112,113, the transcription factor NFAT (nuclear 
factor of activated T cells)114, the nuclear factor-κB (NF-κB) regulating protein (MURR1)115, 
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and polypyrimidine-tract-binding protein (PTB)116 have been shown to block HIV-1 replication 
after its entry into resting CD4+ T cells, although the relevance of these cellular restriction 
factors in DCs is not fully studied. Expression levels of APOBEC3G have been shown to 
correlate with resistance of mDCs to HIV-1.117APOBEC3G upregulation by IFNα has been 
shown to restrict HIV-1 infection in pDCs.118Also, engagement of the receptors CCR5 and CD40 
with CCL3 andCD40L respectively, enhances the expression of APOBEC3G in DCs through 
activation of the ERK 1/2 and p38 MAP kinase signaling pathways; and3) DCs express low 
levels of HIV-1 receptor, CD4, as well as co-receptors, CCR5), and CXCR4.119 HCV co-receptor 
claudin1 is also present at very low levels in DCs.107 HIV-1 and HCV entry receptors are 
reviewed in next section.  
HIV-1 uptake by DCs has recently been shown to trigger TLR8 (via ssRNA), which 
results in phosphorylation of RNA Polymerase II (RNAPII) at serine 2 of the C-terminal domain 
(CTD).118 On the other hand, binding of HIV-1 envelope protein gp120 with DC-SIGN results in 
activation of Raf-1 leading to phosphorylation of p65 at serine 276. This modification on p65 
recruits positive transcription elongation factor b (p-TEFb) to the long terminal repeat (LTR), 
which phosphorylates RNAPII at serine 5 of CTD.118 It has been shown that phosphorylation of 
RNAPII at both serine 2 and serine 5 of its CTD promotes full-length transcription of the 
integrated HIV-1 genome and production of HIV-1 proteins. Thus, HIV-1 induces innate 
signaling by TLR8 as well as DC-SIGN, and that allows it to cause productive infection of DCs. 
Despite this, the frequency of blood DCs productively infected with HIV-1 is low. This could be 
due to increased migration of these DCs from blood to lymph nodes or due to their increased rate 
of apoptosis. Interestingly, HCV glycoprotein E2 is known to interact with DC-SIGN120and this 
interaction has been shown to activate p38 MAPK pathway (possibly leading to activation of 
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Raf-1). Therefore, it would be interesting to study whether HCV can augment HIV-1 replication 
in DCs during HIV-1/HCV co-infection. 
 
Impact of chronic HIV-1 and HCV infections on DCs 
Various studies suggest that DCs play an important role in controlling HIV-1 and HCV infection. 
Individuals in whom HCV infection is cleared spontaneously, or in whom HIV-1 infection is 
controlled, have strong multi-epitope-specific CD4+ and CD8+ T-cell responses, which probably 
reflects efficient antigen presentation and T-cell activation potential of DCs121-124. However, the 
chances of viral clearance after HCV and HIV-1 infection are low, owing to the remarkable 
ability of these viruses to evade the host immune response and establish chronic infection. It has 
been shown that viral persistence might be facilitated by its successful impairment of DC 
functions. At the primary level, viruses can modulate the frequency of various DC subsets by 
causing their aberrant trafficking, inducing apoptosis, or interfering with their development. 
Compared with uninfected individuals, HIV-1-infected15,125-129 as well as HCV-infected130-135 
individuals have lower numbers of mDCs and pDCs. During HIV-1 infection, pDCs migrate to 
the inflamed lymph nodes, where they become activated, apoptotic, and, frequently, infected 
with the virus.136,137 During HCV infection, blood DCs are enriched in liver134,138,139 suggesting 
that increased migration of DCs to liver (which is the primary site of HCV replication) causes the 
observed drop in blood DC count. Other possibilities are that HCV targets DC precursors, as 
reported by Sansonno et al.140, or that HCV directly targets DCs to reduce their numbers. In this 
regard, it has been shown that HCV core, NS3, and NS5 proteins induce apoptosis in mature 
DCs in vitro.141 Interestingly, in vitro studies have shown that HCV envelope glycoprotein E2, as 
well as sera from HCV-infected patients, inhibits the migration of DCs towards CC-chemokine 
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ligand 21 (CCL21), a CCR7 binding chemokine that is important for their homing to lymph 
nodes.134 This leads us to an intriguing hypothesis that HCV impairs the ability of DCs to 
migrate to the draining lymph nodes, causing them to get trapped in the liver. This hypothesis 
has not been thoroughly investigated in vivo. 
Under different immunological states, DCs can either produce IL-12 or IL-10. While IL-
12 promotes the differentiation of CD4+ and CD8+ T cells toTH1 cells and CTLs respectively, IL-
10 is capable of inhibiting the same62. MDDCs, mDCs, and pDCs from HIV-1-infected142-144 and 
HCV-infected133,135,145,146 individuals have been shown to upregulate IL-10, and downregulate 
IL-12 and IFNα production in response to various maturation stimuli. Furthermore, the ability of 
NK cells to mediate early antiviral defense might be affected by dysregulated production of 
cytokines by DCs. Several studies indicate that defective pDC function during HIV-1 infection 
contributes towards impaired NK cell activity, particularly their ability to secrete IFNγ147,148.  
Compared to uninfected individuals, DCs isolated from individuals infected with HIV142-
144 and HCV133,149-151 were found to be less efficient in stimulating T-cell activation and 
proliferation, as seen in mixed lymphocyte reaction. This inefficient allogenic T-cell stimulation 
by DCs isolated from HIV-1152 and HCV-infected151 patients could be reversed by neutralization 
of IL-10, suggesting that virus-induced production of IL-10 by DCs could skew the immune 
response towards tolerance by limiting T-cell activation and proliferation. To gain a different 
perspective on the impact of HIV-1 and HCV on DCs, various studies have investigated DC 
function and numbers before and after antiviral therapy. Highly active antiretroviral therapy for 
treating HIV-1 infection has been shown to restore pDC count as well as IFNα production to 
normal levels147,153. Similarly, in HCV-infected patients that were able to clear the virus upon 
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IFN/RBV treatment, frequency of pDCs increased substantially and ultimately reached normal 
levels154. 
 
Molecular basis of virus-DC interaction 
To understand the molecular mechanisms of interaction between these two viruses and DCs, 
various in vitro studies have used DC subsets isolated from uninfected individuals and exposed 
them directly to the recombinant infectious virus or viral proteins. Unlike HIV-1 and many other 
viruses such as influenza virus and herpes simplex virus 1, recombinant and serum-derived HCV 
have been shown to be poor inducers of IFNα production in pDCs, suggesting that HCV might 
inhibit IFNα production by pDCs as a strategy to escape IFNα-mediated immune response 
against itself. In pDCs, TLR7 and TLR9 are endosomal TLRs, responsible for detecting viral 
RNA and DNA, respectively. Detection of viral RNA or DNA leads to the activation of NF-κB 
and IFN-regulatory factors, which control the transcription of type I IFNs (IFNα, IFNβ) and 
various proinflammatory cytokines. IFNα production induced by CpG oligodeoxynucleotide (a 
TLR9 agonist), but not by resiquimod (a TLR7 agonist), is inhibited by HCV79,80,164. HIV-1 is 
also known to impair IFNα production by pDCs, indicating that impaired production of IFNα by 
pDCs might be a common strategy employed by many viruses to establish a persistent infection. 
Hepatitis B virus envelope protein HBsAg and HIV-1 envelope protein gp120 have been shown 
to impair TLR9-mediated IFNα production through binding to a C-type lectin, blood DC antigen 
2 (BDCA2; also known as CLEC4C).155,156 HCV core particles and recombinant noninfectious 
HCV particles composed of HCV core 105 and envelope glycoproteins E1 and E2105,106,157 have 
been shown to block TLR9-mediated IFNα production, but whether BDCA2 plays a role in that 
as well is not known. Interestingly, Takahashi et al.158 have provided evidence that pDCs that 
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infiltrate the liver during HCV infection could be a major source of type I IFNs. In these studies, 
co-cultivation of pDCs with HCV-infected hepatocytes resulted in marked IFN production in 
proportion to the number of HCV-infected cells. IFN production was mediated by TLR7, and not 
TLR9, a finding consistent with earlier studies reporting that HCV inhibits TLR9 but not the 
TLR7-mediated pathway to suppress IFN production.79,80,164This essentially helps explain why 
infection with HCV leads to a robust expression of IFN-stimulated genes in liver159,160 despite its 
remarkable ability to attenuate IFN production by infected hepatocytes (reviewed here161).  
Recent studies have shown that persistent viruses can induce the activity of 
immunosuppressive enzymes in DCs, which leads to suppression of antiviral T-cell response. 
Tryptophan-catabolizing indoleamine 2,3 dioxygenase (IDO) activity seems to play a central role 
in the suppressive function of DCs.162 On direct exposure to HIV-1, DCs induce IDO activity, 
which leads to inhibition of CD4+ T-cell proliferation in vitro.163 Also, HIV-1-induced IDO 
activity in pDCs leads to differentiation of naive T cells into CD4+CD25+FOXP3+ regulatory T 
cells with suppressive function164. In simian immunodeficiency virus-infected macaques, IDO 
activity peaked at the same time as the increase in plasma viremia as well as expansion of the 
CD4+CD25+FOXP3+ T-cell subset, which may play an important role in curbing the SIV-specific 
CD4+ T-cell response.165Enhanced IDO activity is found in both HIV-1 and HCV-infected 
patients; thus further investigation is needed to completely understand its role in the regulation of 
the cellular immune response against these viruses.  
Weak DC response in HIV-1 and HCV-infected patients acts as a double-edged sword. 
Besides being ineffective at clearing these viruses, it leads to chronic immune activation. 
Systemic chronic immune activation is already believed to be the primary driver of HIV-1 
disease progression, and now the focus is on understanding its role in the development of liver 
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fibrosis, cirrhosis, or hepatocellular carcinoma in HCV-infected patients. Recent reports have 
shown that chronic pDC stimulation and IFNα production in HIV-1-infected individuals are 
associated with higher risk of progression to AIDS. It is thus becoming increasingly important to 
understand the role of DCs in HIV-1 and HCV-mediated disease progression. 
 
Immune response in the liver: Role of hepatic antigen presenting cells 
Besides liver-resident DCs, several other liver cell populations such as LSECs, stellate cells, and 
Kupffer cells166 can present antigens and influence the antiviral immune response. However, 
these APCs exist in a state of active tolerance, thus contributing towards a tolerogenic liver 
environment, as evidenced by spontaneous acceptance of liver allografts.167 These liver APCs 
continuously secrete immunosuppressive cytokines such as IL-10 and TGFβ1.168 This raises the 
question of whether the tolerogenic properties of liver APCs contribute towards the 
establishment of persistent HCV infection and whether liver is a site favoring the evasion of 
immune response against HCV as well as other viruses. 
Because access to liver biopsies from HCV-infected as well as HIV-1/HCV co-infected 
patients is limited and because isolating adequate numbers of hepatic APCs is difficult, limited 
information is available about the role of hepatic DCs in HCV infection. Kupffer cells and 
LSECs do not support HCV replication. In vivo studies have demonstrated that hepatic DCs and 
LSECs can present exogenous antigen to naïve T cells, but this does not lead to effective T-cell 
response, either due to inhibition of T-cell polyfunctionality or due to acquisition of an 
immunosuppressive phenotype by T cells. Uptake of viral particles by hepatic APCs may prime 
CD4+CD25+FOXP3+ regulatory T cells, which are known to dampen the CD8+ T-cell response. 
This results in failure of the immune system to eradicate the virus from the liver. In chronic HCV 
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infection, antigen-specific CD8+ T cells in liver are frequently reported to become dysfunctional 
and unable to secrete IFNγ and IL-2169. In light of these observations, it becomes important to 
further investigate the role of hepatic APCs in HCV-specific T-cell priming.  
The antigen presentation ability of hepatocytes has not been studied thoroughly, as they 
are generally inaccessible to naive T cells because of the barrier formed by LSECs. However, 
electron microscopy studies have shown that hepatocytes contain microvilli that can pass through 
the fenestrations in the endothelium, allowing them to make contact with naive T cells in the 
sinusoidal lumen.170 Normally, hepatocytes do not express MHC class II molecules, but aberrant 
expression of MHC class II molecules has been noted during clinical hepatitis171,172. Therefore, it 
will not be unreasonable to believe that hepatocytes can induce HCV-specific CD4+ T cells or 
modulate the antiviral activity of pre-activated CD4+ T cells. Studies on transgenic mice have 
also shown that hepatocytes can directly stimulate CD8+ T cells, although the cells seem to lack 
cytotoxicity, possibly due to absence of co-stimulatory molecules on hepatocytes.173,174 
 
Type I Interferons 
Interferons (IFNs) are widely expressed cytokines that are known for their antiviral, anti-
proliferative and immunomodulatory effects175,176. The IFN family includes two main classes of 
related cytokines: type I IFNs and type II IFN177,178. Type I IFNs family includes several 
members with considerable structural homology. These include IFN-α (further subdivided into 
13 different subtypes, IFN-α1, -α2, -α4, -α5, -α6, -α7, -α8, -α10, -α13, -α14, -α16, -α17 and -α21), IFN-β, IFN-δ, IFN-ε, IFN-κ, IFN-τ and IFN-ω179. IFN-α, IFN-β, IFN-ε, IFN-κ and IFN-ω 
exist in humans, whereas IFN-δ and IFN-τ have been described only for pigs and cattle, 
respectively, and do not have human homologues. All type I IFNs signal through heterodimeric 
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complex of type I IFN receptor (IFNAR1) and IFNAR2. Type I interferon initially binds to 
IFNAR2 (with high affinity) which subsequently results in its dimerization with IFNAR1180. 
IFNAR1 subunit is constitutively associated with tyrosine kinase 2 (TYK2), whereas IFNAR2 is 
associated with JAK1. Dimerization of IFNAR1 and IFNAR2 brings the two tyrosine kinases in 
close proximity, causing them to trans-phosphorylate and activate each other. The activated 
kinases phosphorylate the receptors. The receptor phosphotyrosine residues direct the SH2-
dependent recruitment of signal transducer and activator of transcription (STAT) family 
members, STAT1 and STAT2, which in turn become phosphorylated at a tyrosine residue 
(Y701) conserved among all STAT family members. Phosphorylated (activated) STAT1 and 
STAT2 are released from the receptor as they reorient into an anti-parallel dimer, where the SH2 
domain of STAT1 binds the phosphotyrosine of STAT1181,182. STAT1-STAT2 heterodimer binds 
to IFN-regulatory factor 9 (IRF9) in the cytoplasm. STAT1-STAT2-IRF9 complex known as 
Interferon-stimulated gene factor 3 (ISGF3) undergoes nuclear translocation mediated by 
Importin-α5183. Inside nucleus, ISGF3 binds to IFN-stimulated response element (ISRE) 
sequences to activate classical antiviral genes (such as OAS, MX1). The type I IFN signalling 
pathway described above is the canonical pathway. IFNAR1, IFNAR2, JAK1, TYK2, STAT1, 
STAT2 and IRF9 are ubiquitously expressed and therefore most cell types are capable of 
mounting type I IFN responses. Other than canonical pathway, type I IFNs can also trigger the 
activation of other STAT family members such as STAT3, STAT4, STAT5 and STAT6176,184 in 
a cell-type and context-dependant manner. Type I IFNs also mediate their cellular effects 
through Mitogen-activated protein kinase (MAPK) pathway and phosphatidylinositol 3-kinase 
(PI3K) pathway178. A greater understanding of mechanisms of action of type I IFNs will enable 
us to develop rational therapies that promote resolution of viral infections without any associated 
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damage to the host. 
 
Type III Interferons 
Type III IFNs namely IFN-λ1 (IL-29), IFN-λ2 (IL-28A), and IFN-λ3 (IL-28B), is the newest 
class of IFNs discovered in 2003185,186. Type III Interferons signal through a heterodimeric 
receptor complex (IFN-λR) that consists of a unique ligand-binding chain, IFN-λR1, and an 
accessory chain, IL-10R2, which is shared with receptors for IL-10-related cytokines (IL-10, IL-
22 and IL-26). IFN-λR1 and IL-10R2 are constitutively associated with JAK1 and TYK2 
respectively. Binding of type III IFNs to IFN-λR leads to activation of JAK1 and TYK2 
resulting in tyrosine phosphorylation of IFN-λR1 and subsequent activation (by 
phosphorylation) of STAT1 and STAT2185,187. It can also induce activation of STAT3, STAT4, 
and STAT5 in some cell types188. Activated STAT1 and STAT2 form a heterodimer and form 
trimeric ISGF3 complex with IRF9. ISGF3 translocates to nucleus and binds to IFN-stimulated 
response element (ISRE) sequences to activate classical antiviral genes. Interestingly, although 
type I and type III IFNs signal through different receptor complexes, they activate the same 
intracellular signaling pathway. Studies have shown that type III IFNs induce similar ISG 
profiles as type I IFNs and can inhibit HCV replication in vitro189. However, unlike ubiquitously 
expressed type I IFN receptors, type III IFNs receptors are largely restricted to cells of epithelial 
origin suggesting a localized role of type III IFNs in antiviral defense. Interestingly, the kinetics 
of ISGs induction differs between type I and type III IFNs, with type I IFNs inducing a more 
sustained expression of ISGs compared to IFN-α190. Also, IFN-λ signaling, unlike IFN-α 
signaling, does not become refractory to repeated stimulation191, and can function cooperatively 
with IFN-α to impart enhanced ISGs induction and antiviral activity192. Therefore, type III IFNs 
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may provide a localized, sustained activation of ISGs in specific cell types in HCV-infected liver 
and prime an effective immune response against HCV. In fact, clinical studies have 
demonstrated that IFN-λs can be effective anti-HCV agents with fewer side effects than IFN-α. 
 
MicroRNAs: Biogenesis and mechanisms of action 
MicroRNAs (miRNAs) are short (20–23-nucleotides), single-stranded, non-coding RNA 
molecules that play important role in post-transcriptional regulation of gene expression193. 
Mature miRNAs and Argonaute (Ago) proteins form RNA-induced silencing complex, a 
ribonucleoprotein complex mediating post-transcriptional gene silencing194,195. MicroRNA genes 
can either be individual or as gene clusters transcribed as polycistronic units196,197. Recent studies 
have shown the importance of clustering of miRNA genes from a functional standpoint. Many 
miRNA clusters coordinately regulate multiple members of cellular signaling pathways or 
protein interaction networks. This cooperative method of targeting is able to produce greater 
effects on a process compared to individual miRNAs. Studies suggest that approximately half of 
known miRNAs reside within the introns of protein coding genes198. 
Transcription of miRNA genes by RNA polymerase II generates long primary transcripts 
(pri-miRNAs) (Fig.1.4). Within nucleus, the nuclear microprocessor complex formed by RNase 
III enzyme Drosha and DGCR8 (DiGeorge critical region 8) protein processes pri-miRNA, 
yielding a hairpin precursor (pre-miRNA) approximately 70 nucleotides long. The pre-miRNA is 
exported into the cytoplasm (by Exportin-5 in complex with Ran-GTP) where it is further 
processed into 19-25 nucleotide long miRNA duplex by the RNase III Dicer199. After Dicer-
mediated cleavage, Dicer and Dicer-associated proteins TRBP dissociate from the miRNA 
duplex. To form the active RISC that performs gene silencing, the double-stranded duplex needs 
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to be separated into the functional guide strand, which is complementary to the target, and the 
passenger strand (or star stand), which is subsequently degraded. Although multiple helicases 
have been linked to the miRNA pathway, a universal helicase responsible for duplex unwinding 
has not yet been identified. Helicases associated with RISC formation or activity includes p68, 
p72, RNA helicase A (RHA), RCK/p54, TNRC6B, Gemin3/4 and Mov10200-203. There are 
instances where the star strand is not degraded and performs its individual functions (such as 
miR-155 and miR-155*)204  
After functional miRNA strand and Argonaute (Ago) proteins form RNA-induced 
silencing complex, miRNA binds to its target mRNA and can either lead to its translational 
repression by: inhibition of translation initiation; inhibition of translation elongation; co-
translational protein degradation; and premature termination of translation205-209. Alternatively, 
miRNAs can direct endonucleolytic cleavage of fully complementary mRNA targets210 (rare in 
animal cells) or direct the 5’ to 3’ decay of partially complementary mRNA targets. The decay of 
mRNA targets is initiated by the removal of poly (A) tail by deadenylases followed by decapping 
and subsequent 5′-to-3′ exonucleolytic digestion of mRNA. 
 
Summary 
In our study, we were able to identify IFN-α-regulated miRNAs in mDCs and pDCs isolated 
from healthy donors. Among many miRNAs whose expression was modulated upon IFN 
treatment, miR-155 and miR-221 were studied in more detail due to their previously established 
roles in DC functions. miR-155 was upregulated in mDCs but not pDCs, whereas miR-221 was 
downregulated in both mDCs and pDCs. During ex vivo studies with PBMCs from HIV-1/HCV 
individuals on PEG-IFN/RBV therapy, we were able to demonstrate a correlation between  
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Figure 1.4: Canonical miRNA processing pathway (Winter et al, Nature Cell Biology, 
2009). The first step is transcription of miRNA genes by RNA polymerase II to generate primary 
miRNA transcript (pri-miRNA). The Drosha–DGCR8 microprocessor complex in the nucleus, 
cleaves pri-miRNA. The resulting precursor hairpin, the pre-miRNA, is exported f`rom the 
nucleus by Exportin-5–Ran-GTP. In the cytoplasm, the RNase Dicer in complex with the 
double-stranded RNA-binding protein TRBP cleaves the pre-miRNA hairpin to its mature 
length. The functional strand of the mature miRNA is loaded together with Argonaute (Ago2) 
proteins into the RNA-induced silencing complex, where it guides RISC to silence target 
mRNAs through mRNA cleavage, translational repression or deadenylation, whereas the 
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treatment response and the expression of IFN-regulated miRNAs (miR-221 and miR-155) as 
well as IFN-regulated mRNAs (ISGs). Although ISGs expression in liver is a good predictor of 
treatment response, obtaining liver biopsies from the infected patients is not always feasible. 
Therefore, identification of treatment response-associated molecular signatures in PBMCs will 
be useful in the clinical management of HIV-1/HCV co-infection. We were also able to 
characterize changes in DC phenotype in NRs and SVRs both before and during the treatment. 
We are confident that this work will prove to be beneficial for both diagnostic purposes and for 
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HIV-1/HCV co-infection is a significant health problem. Highly active antiretroviral treatment 
(HAART) against HIV-1 is fairly effective. On the other hand, direct acting antiviral drugs 
against HCV have improved cure rates but high cost and development of drug resistance are 
important concerns. Therefore PEGylated interferon (PEG-IFN) and ribavirin (RBV) are still 
essential components of treatment, and identification of host factors that predict IFN/RBV 
treatment response is imperative. Impaired dendritic cell 1 and T cell responses are associated 
with HCV persistence. It has been shown that IFN/RBV treatment enhances HCV-specific T cell 
functions and it is likely that functional restoration of DCs is the underlying cause. To test this 
hypothesis, we utilized an antibody cocktail (consisting of DC maturation, adhesion and other 
surface markers) to perform comprehensive phenotypic characterization of myeloid DCs (mDCs) 
and plasmacytoid DCs (pDCs) in a cohort of HIV-1/HCV co-infected individuals undergoing 
IFN/RBV treatment. Our results showed that pre-treatment frequencies of mDCs were lower in 
non-responders (NRs) compared to responders (SVRs) and healthy controls. The treatment was 
able to restore the frequency of mDCs in NRs, but it downregulated the frequency of CCR7+, 
CD54+ and CD62L+ mDCs. Pre-treatment pDC frequencies were lower in NRs and decreased 
further upon treatment. NRs exhibited reduced frequency of CCR7+ pDCs and increased pDC 
PD-L1/CD86 ratio as a result of treatment. These findings demonstrate that functional state of 
DCs before/during therapy influences the treatment outcome. We also show that before 
treatment, PBMCs from SVRs secrete higher amounts of IFN-γ compared to controls and NRs. 
Upon genotyping IFNL3 polymorphisms rs12979860, rs4803217 and ss469415590, we found 
rs12979860 to be a better predictor of treatment outcome. Collectively, our study led to 
identification of important correlates of IFN/RBV treatment response in patients. 
51




Chronic infections with human immunodeficiency virus 1 (HIV-1) and hepatitis C virus (HCV) 
are a leading cause of morbidity and mortality worldwide. Chronic infection with HIV-1 causes 
acquired immunodeficiency syndrome2, which is characterized by severe immunosuppression 
and associated opportunistic infections, whereas chronic HCV infection causes chronic liver 
disease and its associated complications such as liver cirrhosis, liver failure and hepatocellular 
carcinoma3. Up to 30% of HIV-infected individuals overall and 60-90% of HIV-infected 
injection drug users are infected with HCV4-6 and therefore HIV-1/HCV co-infection is a 
significant health problem. Since co-infection with HIV-1 is known to have a negative impact on 
HCV pathogenesis and disease progression, it is recommended that in individuals with HIV-
1/HCV co-infection, HIV-1 be controlled prior to initiation of HCV treatment7. PEG-Interferon-
α (PEG-IFN) in combination with nucleoside analog ribavirin (RBV) has been the mainstay of 
chronic HCV treatment but unlike HAART it has been difficult because of limited success rate 
(~50%) and toxic side effects. Both PEG-IFN and RBV have nonspecific and largely unknown 
mechanisms of action and therefore in the last few years direct-acting antiviral agents (DAAs) 
have been developed and approved for treating HCV. Administration of DAAs with/without 
IFN/RBV has improved cure rates but the high cost of DAAs along with emergence of drug-
resistant HCV variants remain important concerns. Therefore, for better clinical management of 
HCV, it is necessary to identify host factors that predict the outcome of IFN/RBV treatment. 
Individuals with undetectable HCV RNA levels six months or longer after IFN/RBV treatment 
are referred to as sustained virological responders (SVRs) and those that fail to clear HCV after 
treatment are referred to as non-responders (NRs).  
As sentinels of our immune system, DCs play a central role in initiating and regulating 
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protective antiviral immunity. Immature DCs express inflammatory chemokine receptor CCR5 
whose interaction with chemokine CCL5 promotes their recruitment to the site of infection. At 
the site of infection, DCs sense viral signatures through pattern recognition receptors (PRRs) and 
become activated. Upon activation, DCs undergo a process of maturation which involves 
increase in the surface expression of major histocompatibility complex (MHC) class I and II 
molecules, co-stimulatory molecules (such as CD86), adhesion molecules (such as CD54 and 
CD62L) and lymph node homing receptors (such as CCR7)8. The cellular immune response has 
a profound impact on outcome and pathogenesis of HCV infection9. Poor CD4+ and CD8+ T cell 
response is a hallmark of chronic HCV infection10. Being professional antigen presenting cells, 
DCs play a crucial role in directing an efficient antiviral T-cell response. Functional defects in 
DCs have been shown to underlie weak and narrowly focused T cell response characteristic of 
chronic HCV infection11,12. Compared to uninfected individuals, DCs isolated from HCV-
infected individuals are less efficient in stimulating T cell activation and proliferation12-15. HCV-
infected individuals have increased expression of programmed death-ligand 1 (PD-L1) on 
DCs16,17. Binding of PD-L1 to programmed cell death protein 1 (PD-1) expressed on T cells 
delivers a coinhibitory signal to T cells resulting in their reduced proliferation and effector 
functions. Also, HIV-1-infected18-22 and HCV-infected12,23-25 individuals have reduced 
frequencies of mDCs and pDCs compared to uninfected individuals. Since IFN/RBV therapy is 
known to enhance HCV-specific CD4 and CD8 T-cell response in SVRs, it is possible that 
IFN/RBV therapy restores both DC frequencies and functions in SVRs but not in NRs. To this 
end, we investigated whether the treatment differentially affects DC frequencies, phenotype and 
functions in NRs and SVRs. We also genotyped three important SNPs associated with treatment 
response. Collectively, our study helped identify the genetic and immune correlates of IFN/RBV 
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treatment response in HIV-1/HCV individuals. Our findings will also be helpful in development 
of DC-based immunotherapeutic strategies against HCV  
 
Results 
Impact of SNPs rs12979860, rs4803217 and ss469415590 on the outcome of PEG-IFN/RBV 
treatment in HIV-1/HCV co-infected individuals 
Genome-wide association studies have identified a single nucleotide polymorphism (SNP) 
rs12979860 (CC>CT>TT) which is strongly associated with treatment-induced as well as 
spontaneous clearance of HCV in HCV mono-infected as well as HIV-1/HCV co-infected 
individuals26. It is located upstream of IFNL3 (which encodes IFN-λ3, also known as interleukin 
28B). However, the molecular mechanisms underlying this association have remained unclear. 
Recently, rs480321727 and ss46941559028 that are in linkage disequilibrium with rs12979860 
have been identified as functional SNPs (All three SNPs are schematically represented in Fig. 
2.1A). rs4803217 (GG>GT>TT) located in 3’ UTR of IFNL3 directs the outcome of HCV 
infection by influencing IFNL3 mRNA stability. ss469415590 (TT/TT>ΔG/TT>ΔG/ΔG) located 
upstream of IFNL3 has also been reported to affect HCV clearance. The unfavorable allele 
(represented as ΔG) is characterized by deletion of a single base, which causes a frameshift 
mutation leading to expression of a novel protein IFNL4. It is suggested that IFNL4 induces a set 
of unfavorable genes that allow increased viral replication and therefore its absence from HCV-
infected cells has a protective effect against HCV. The effect of rs4803217 and ss469415590 on 
IFN/RBV treatment-induced HCV clearance is not extensively studied in HIV-1/HCV co-
infected individuals. Herein, we investigated the association between these three SNPs and 
IFN/RBV treatment response in a cohort of HIV-1/HCV co-infected individuals (infected with 
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HCV genotype 1a which is a difficult to treat genotype compared to genotypes 2 and 3). Fig. 
2.1B shows the race, sex, treatment response and genotypes of all three SNPs. As expected, 
rs12979860 showed a strong association with treatment response with ~60% of individuals with 
the most favorable genotype CC and only 25% of individuals with the least favorable genotype 
TT achieving sustained virological response (SVR) (Fig. 2.1C). In our cohort, no individual 
possessed the most favorable rs4803217 genotype 29 (Fig. 2.1D). Approximately 33% of the 
individuals with intermediate genotype GT and only 25% of the individuals with least favorable 
genotype TT cleared the virus (Fig. 2.1D). Approximately 33% of the individuals with most 
favorable ss469415590 genotype TT/TT and only 25% of the individuals with least favorable 
genotype ΔG/ΔG cleared the virus (Fig. 1E). Overall, our study shows that rs12979860 is a 
much better predictor of SVR in HIV-1/HCV co-infected individuals (carrying HCV genotype 1) 
compared to rs4803217 and ss469415590.  
 
Effect of IFN/RBV treatment on the frequency of mDCs and pDCs. Various studies have 
shown that HIV-1- and HCV-infected individuals have reduced frequency of mDCs and pDCs in 
blood, however the impact of HIV-1/HCV co-infection on DC frequency and functions is not 
completely understood. In our study we used flow cytometry based thirteen-color antibody 
cocktail (details are mentioned in supplementary Fig. 2.1A) for enumeration and phenotypic 
assessment of two subsets of DCs: mDCs (CD11c+/CD123-) and pDCs (CD11c-/CD123+). We 
observed that prior to initiation of IFN/RBV treatment, NRs had significantly lower frequency of 
mDCs compared to SVRs and seronegative controls (Fig. 2.2A). Frequency of pDCs in NRs was 
significantly lower compared to controls but not compared to SVRs (Fig. 2.2B). Next, we 
investigated whether IFN/RBV treatment restores the frequency of mDCs and pDCs  
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Figure 2.1: Impact of SNPs rs12979860, rs4803217 and ss469415590 on the outcome of 
PEG-IFN/RBV treatment in HIV-1/HCV co-infected individuals. (A) Schematic representing 
the location of IFNL1-4 on chromosome 19. SNPs rs12979860 and ss469415590 are located 
upstream of IFNL3 whereas SNP rs4803217 is harbored in the 3’ UTR of IFNL3. (B) Table 
showing the race, sex, treatment response as well as rs12979860, rs4803217 and ss469415590 
genotypes (determined using custom designed TaqMan qPCR based allelic discrimination assay, 
Life Technologies) in a cohort of HIV-1/HCV co-infected individuals utilized in the study. (C) 
Bar graph indicating the percentage of sustained virological responders in individuals carrying 
the given rs12979860 genotype (CC/CT/TT). (D) Bar graph indicating the percentage of 
responders in individuals carrying the given rs4803217 genotype (GG/GT/TT). (E) Bar graph 
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in NRs. We found that by end of treatment, the frequency of mDCs increased in NRs (Fig. 2.2C) 
but the frequency of pDCs decreased further (Fig. 2E). On the other hand, DC frequency 
remained unchanged in SVRs (Fig. 2.2D and 2.2F).  
 
IFN/RBV treatment downregulates the percentage of mDCs expressing CCR7 in NRs. In 
addition to direct antiviral effects, IFN-α plays an important role in shaping the immune 
response by regulating the maturation, migratory potential and immunostimulatory capacity of 
DCs. Upon maturation, DCs upregulate CCR7 expression. Failure to upregulate CCR7 inhibits 
the migration of DCs towards CCL21, a CCR7 binding chemokine that is important for homing 
of DCs to lymph nodes. We hypothesized that even though IFN/RBV treatment led to restoration 
of mDC frequency in NRs, the potential of mDCs to migrate to lymph nodes and activate T cells 
could still be impaired. In this regard, we found that upon treatment, the percentage of mDCs 
expressing CCR7 was reduced in NRs (Fig. 2.3A) but not in SVRs (Fig. 2.3B). At the end of 
treatment, the frequency of CCR7+ mDCs was lower (although statistical significance did not 
reach 95% confidence interval) in NRs compared to controls. On the other hand, percentage of 
pDCs expressing CCR7 remained unchanged in both NRs (Fig. 2.3C) and SVRs (Fig. 2.3D). 
This shows that diminished frequency of CCR7+ mDCs during the first four weeks of IFN/RBV 
treatment could be a key event in treatment failure. 
 
Effect of IFN/RBV treatment on DC adhesion markers CD54 and CD62L. IFN-α is known 
to upregulate the adhesion molecules CD54 and CD62L on DCs. Both CD54 and CD62L play an 
important role in DC-T cell interaction that results in activation of T cells. We investigated the 
percentage of DCs expressing CD54 and CD62L in NRs and SVRs both before and during the 
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course of treatment. We found that prior to treatment, both NRs (Fig. 2.4A) and SVRs (Fig. 
2.4B) had significantly higher frequency of CD54+ mDCs compared to controls. On the other 
hand, frequencies of CD62L+ mDCs prior to treatment were similar in controls and infected 
individuals (Fig. 2.4C and 2.4D). Upon initiation of IFN/RBV treatment, the frequency of CD54+ 
and CD62L+ mDCs dropped in both NRs and SVRs (Fig. 2.4A-D). Interestingly, the post-
treatment frequencies of CD62L+ mDCs were significantly lower than controls. This suggests 
that IFN/RBV may have a long-term adverse effect on DC functions in both NRs and SVRs. 
SVRs had higher pre-treatment frequency of CD54+ mDCs and it remained higher throughout 
the course of treatment (Fig. 2.4F). Similar to mDCs, pre-treatment frequencies of CD62L+ 
pDCs were similar in controls and infected individuals, but upon treatment it dropped 
significantly in NRs.  
 
Increased PD-L1/CD86 ratio on pDCs of NRs before and after IFN/RBV treatment. HIV-
1/HCV co-infection is characterized by poor, narrowly focused and exhausted HCV-specific T 
cell response. Our group and others have shown that persistent viruses such as HTLV-1, HIV-1 
and HCV can cause T cell exhaustion by upregulating the expression of PD-1 (on T cells) and 
PD-L1 (on DCs). Binding of PD-L1 and PD-1 delivers a coinhibitory signal to T cells leading to 
reduced proliferation and effector functions. Since both PD-L1 and CD86 belong to the B7 
family, it is possible that the balance between coinhibitory marker PD-L1 and costimulatory 
marker CD86 regulates the efficiency of effector T cell response. To test this hypothesis, we 
examined CD86 and PD-L1 expression on both DC subsets. As shown in Fig. 5A, PD-L1/CD86 
ratio of mDCs did not vary significantly between controls and infected individuals. However, the 
PD-L1/CD86 ratio of pDCs was significantly higher in NRs compared to SVRs (Fig. 2.5B) both    
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Figure 2.2: Effect of IFN/RBV treatment on the frequency of mDCs and pDCs in NRs and 
SVRs. PBMCs isolated from seronegative controls, NRs and SVRs were stained with 
polychromatic antibody cocktail described in supplementary Fig. 1. (A) Box and whiskers graph 
indicating the percentage of mDCs, and (B) pDCs in seronegative controls, SVRs and NRs prior 
to initiation of treatment. (C) Box and whiskers graph indicating the percentage of mDCs in 
NRs, and (D) SVRs at different time points during the course of treatment. (E) Box and whiskers 
graph indicating the percentage of pDCs in NRs, and (F) SVRs at different time points during the 
course of treatment. P values were calculated using Student’s t test (* represents P<0.05). 
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Supplementary Figure 1: (A) Composition of polychromatic antibody cocktail used for 
phenotyping peripheral blood DCs of HIV-1/HCV co-infected individuals. Table lists the clone, 
isotype, source and function of each of the antibodies (please note that amine reactive dye is not 
an antibody) used in the cocktail. (B) Gating strategy for defining specific DC subsets. The first 
step is to use forward scatter (FSC)-A vs. side scatter (SSC)-A plot to exclude cellular debris. 
This is followed by using FSC-H vs. FSC-A plot to gate on singlet events. The third step is to 
exclude the dead cells, which are brightly stained with amine reactive dye. Finally, Lin-1- cells 
(comprise DCs and Basophils) are gated out and used for defining mDCs (CD11c+/CD123-) and 
pDCs (CD11c-/CD123+). 
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Figure 2.3: IFN/RBV treatment downregulates the percentage of mDCs expressing CCR7 
in NRs. PBMCs isolated from seronegative controls, NRs and SVRs were stained with 
polychromatic antibody cocktail described in supplementary Fig. 1. (A) Box and whiskers graph 
indicating the percentage of mDCs expressing CCR7 in NRs, and (B) SVRs prior to and during 
the course of IFN/RBV treatment. (C) Box and whiskers graph indicating the percentage of 
pDCs expressing CCR7 in NRs, and (D) SVRs prior to and during the course of IFN/RBV 
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Figure 2.4: IFN/RBV treatment downregulates the frequency of CD54+ mDCs, CD62L+ 
mDCs and CD62L+ pDCs in NRs. PBMCs isolated from seronegative controls, NRs and SVRs 
were stained with polychromatic antibody cocktail described in supplementary Fig. 1. (A) Box 
and whiskers graph indicating the percentage of mDCs expressing CD54 in NRs, and (B) SVRs. 
(C) Box and whiskers graph indicating the percentage of mDCs expressing CD62L in NRs, and 
(D) SVRs. (E) Box and whiskers graph indicating the percentage of pDCs expressing CD54 in 
NRs, and (F) SVRs. (G) Box and whiskers graph indicating the percentage of pDCs expressing 
CD62L in NRs, and (H) SVRs. P values were calculated using Student’s t test (* represents 
P<0.05).  
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before (week 0) and after treatment (week 30-48). Our previous finding (Fig. 2.4G) showed that 
reduction in the frequency of CD62L+ pDCs during IFN/RBV treatment associates with non-
response. Overall, it indicates that impaired pDC functions could underlie the non-response to 
IFN/RBV therapy. 
 
Higher frequency of CCR5+ mDCs in HIV-1/HCV co-infected individuals, but they are 
downregulated in response to treatment. HCV infection is associated with increased 
infiltration of mononuclear inflammatory cells many of which express high levels of CCR5 
receptor. Moreover, high levels of CCL3, CCL4 and CCL5 (chemokines that bind to CCR5) are 
found in the HCV-infected liver. Supporting these studies, we observed higher frequency of 
CCR5+ mDCs in both NRs (Fig. 2.6A) and SVRs (Fig. 2.6B), which dropped by week 4 of 
treatment. On the other hand, pre-treatment frequency of CCR5+ pDCs did not differ 
significantly between the three groups (Fig. 2.6C and 2.6D), however upon treatment it dropped 
in NRs (Fig. 2.6C) but not in SVRs (Fig. 2.6D). 
 
SVRs secrete higher amounts of IFN-γ  prior to treatment. Studies on individuals with acute 
HCV infection have demonstrated that an early, strong and multispecific CD4+ and CD8+ T-cell 
response is related to resolution of infection. Individuals in whom HCV infection is resolved, a 
decrease in viremia coincide with a peak in HCV-specific CD8+ T cells secreting IFN-γ (a type 
II IFN). Other in vitro studies suggest the ability of IFN-γ to directly inhibit HCV replication. As 
an important immunoregulator, IFN-γ potentiates the antiviral effects of IFN-α. It is 
characteristic of TH1 differentiation and also known to enhances the cytotoxic activity of T cells, 
macrophages and natural killer cells. Therefore, in our study, we investigated the ability of 
68
   Dissertation: Mohit Sehgal 
 
Chapter 2 
PBMCs of HIV-1/HCV co-infected individuals to secrete IFN-γ during in vitro culture. We 
found that prior to treatment SVRs secreted higher levels of IFN-γ compared to controls and NRs 
(Fig. 2.7A). By the end of treatment, IFN-γ secretion dropped in SVRs but was significantly 
higher in NRs (Fig. 2.7B). Interestingly, increased levels of IFN-γ by NRs at the end of treatment 
may be indicative of the presence of virus in PBMCs. Interestingly, both HIV-1 and HCV are 
known to infect PBMCs and thus it will be interesting to examine whether treatment induced 
clearance of HCV from PBMCs is an indicator of SVR. We also stimulated PBMCs with a 
cocktail of TLR agonists in order to compare the secretion profile of Th1/Th2/Th17 cytokines 
but did not observe any significant differences (data not shown) between controls and two 
groups. 
 
Materials and Methods 
Clinical samples. A total of 24 HIV-1/HCV co-infected, PEG-IFN-α/RBV treatment naïve 
individuals were recruited from the Hepatitis Clinic of New York/Weill/Cornell Medical Center 
in a cohort study. The study design was approved by the institutional review board of Weill 
Medical College, Cornell University and conforms to the 1975 Helsinki guidelines for the 
conduct of human research. Inclusion criteria required individuals to have detectable HCV RNA, 
be on a stable course of antiretroviral therapy or no antiretroviral agents for at least four weeks 
prior to initiation of IFN/RBV treatment, and to have a CD4+ T-cell count ≥ 100 cells/mm3. 
Individuals were excluded if they had severe depression, immunodeficiency-related opportunistic 
infections, on active substance abuse, or were pregnant or lactating. Subjects were 
subcutaneously injected with 1.5 µg/kg of PEG-INTRON (Schering Plough, Kenilworth, NJ) 
once weekly and a 1000-1200 mg daily dose of RBV (Rebitrol, Schering Plough), taken orally 
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for up to 48 weeks. Individuals with HCV RNA below detection (<29 IU/ml) 24 weeks after 
treatment termination were considered SVRs. Patient blood was withdrawn at multiple time 
points (Week 0, 1, 2, 4, 8, 12, 24, 48 of treatment as well as 24 weeks after treatment)  
 
Isolation of peripheral blood mononuclear cells. Peripheral blood withdrawn from HIV-
1/HCV co-infected individuals and seronegative controls was diluted 1:1 with HBSS and used 
for isolating PBMCs by density gradient centrifugation (400g; 40 minutes) using Ficoll Paque 
Plus (GE Healthcare Life Sciences, Piscataway, NJ). After isolation, PBMCs were washed with 
PBS and cryopreserved using freezing media, 10% DMSO in heat inactivated FBS (Thermo 
Fisher Scientific, Waltham, MA). At the time of experiment, cells were quickly thawed at 37°C, 
washed with RPMI-1640 (Mediatech, Herndon, VA) and then with PBS (containing 2 mM 
EDTA) and immediately used for phenotyping/other experiments. 
 
Immunofluorescent staining of PBMCs with polychromatic flow cytometry antibody 
cocktail. We developed a thirteen-color flow cytometry cocktail comprising of cell viability dye 
(Aqua Blue; Invitrogen, Carlsbad, CA) and twelve antibodies against various DC markers. We 
have previously utilized a similar cocktail in a cohort of HTLV-1-infected asymptomatic carriers 
and diseased individuals. Details of the cocktail and gating strategy used to phenotype DCs are 
mentioned in supplementary figure 1. Briefly, FITC-conjugated Lin-1 (commercially available 
cocktail containing FITC-CD3, FITC-CD14, FITC-CD16, FITC-CD19, FITC-CD20, and FITC-
CD56) was used to gate out non-DCs (Lin-1+ cells). Lin-1- cells were used to gate on mDCs 
(CD11c+CD123-) and pDCs (CD11c-CD123+). Remaining Abs were used to stain for co-
stimulation, maturation, activation, and adhesion markers on both DC subsets. Fluorescence-
70
   Dissertation: Mohit Sehgal 
 
Chapter 2 
minus-one (FMO) controls were used to set the gates. For staining, PBMCs were suspended in 
100 µ l staining buffer (PBS supplemented with 2% FBS and 2mM EDTA) and incubated with 
the Ab cocktail for one hour at 4°C. After incubation, cells were washed with staining buffer, 
fixed with 1% paraformaldehyde and resuspended in PBS. Thereafter the cells were acquired on 
a flow cytometer (BD Biosciences FACSAria) 
 
In vitro stimulation of PBMCs with TLR agonists. Cell culture media used for culturing 
PBMCs consisted of RPMI-1640 supplemented with penicillin (Mediatech, 100 U/ml), 
streptomycin (Mediatech, 100 µ g/ml), HEPES buffer (Mediatech, 10 mM), and 10% heat 
inactivated FBS. PBMCs (2x105 cells in 300 µl culture media in a U-bottom 96-well plate) were 
rested for 45 minutes at 37°C with 5% CO2 and 90% relative humidity followed by no 
stimulation or stimulation with (a) cocktail of TLR1/2 (Pam3CSK4 x 3HCl; working 
concentration of 1µg/ml), TLR3 (Poly I:C; 10µg/ml), TLR4 (LPS; 10µg/ml), TLR6 (Flagellin; 
10µg/ml) TLR7 (Imiquimod; 10µg/ml), TLR8 (ssRNA40; 10µg/ml) and TLR9 (ODN2006; 
5µM) agonists and (b) IFN-α (500 IU/ml) for 24h. After stimulation, cells were centrifuged at 
300 g for 10 minutes and culture supernatant was stored at -80°C for later quantitation of 
Th1/Th2/Th17 cytokines using ELISA. 
 
Quantitation of Th1/Th2/Th17 cytokines using ELISA. Culture supernatants collected from 
TLR agonists- and IFN-treated PBMCs were used to measure the concentration of a panel of 12 
cytokines (IL2, IL4, IL5, IL6, IL10, IL12, IL13, IL17A, IFN-γ, TNF-α, G-CSF, and TGF-β1) 
using Human Th1/Th2/Th17 cytokines multi-analyte ELISA array Kit (SA Biosciences, Qiagen) 
according to manufacturer’s protocol. Briefly, antigen standards (500 ng/ml) corresponding to 
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each of the twelve cytokines were prepared. 50 µ l of assay buffer (supplied with the kit) was 
pipetted into each well of the 96 well plate (every well has a capture antibody specific to a 
cytokine) followed by addition of 50 µ l antigen standards or undiluted culture supernatant in 
appropriate wells. Plate was gently shaken and incubated for 2 hours at room temperature. After 
2 hours, plates were decanted and washed thrice with washing buffer (supplied with the kit) 
followed by incubation with biotin-conjugated detection antibodies for 1 hour at room 
temperature and washed thrice thereafter. In the end, cytokines were detected colorimetrically by 
addition of avidin-horseradish peroxidase solution followed by addition of enzyme substrate. 
 
Genotyping of HIV-1/HCV individuals for SNPs rs12979860, rs4803217 and ss469415590 in 
IFNL genes. Genomic DNA was isolated from PBMCs using SV Wizard genomic DNA 
isolation kit (Promega) and used to genotype SNPs rs12979860, rs4803217 and ss469415590 by 
custom designed TaqMan qPCR based allelic discrimination assays. Following primer pair and 
probes were used for genotyping rs4803217: Forward primer-5′-
GCCAGTCATGCAACCTGAGATTTTA-3′, Reverse primer- 5′-
AAATACATAAATAGCGACTGGGTGACA-3′, Probe for IFNL3-T- 5′-FAM-
TTAGCCACTTGTCTTAAT-NFQMGB-3′, and Probe for IFNL3-G- 5′-VIC-
TAGCCACTTGGCTTAAT-NFQMGB-3′; rs12979860: Forward primer- 5′-
GTGCCTGTCGTGTACTGAACCA-3′, Reverse primer- 5′-AGCGCGGAGTGCAATTCA-3′, 
Probe for IFNL3-C- 5′-FAM-CCTGGTTCGCGCCTT-NFQMGB-3′, Probe for IFNL3-T: 5′-
VIC-CCTGGTTCACGCCT-NFQMGB-3′; ss469415590: Forward primer-5′-
GCCTGCTGCAGAAGCAGAGAT-3′, Reverse primer- 5′-GCTCCAGCGAGCGGTAGTG-3′, 
Probe for IFNL3-ΔG- 5′-FAM-ATCGCAGCGGCCC-NFQMGB-3′, and Probe for IFNL3-TT- 
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5′-VIC-ATCGCAGAAGGCC-NFQMGB-3′(where 'FAM' is 5-carboxyfluorescein, 'NFQMGB' 
is a nonfluorescent quencher minor groove binder, and 'VIC' is 6-carboxyrhodamine). Amount of 
genomic DNA used per qPCR reaction ranged from 1-3 ng. 
 
Statistical Analysis. Statistical significance between controls, NRs and SVRs was determined 
using Student's two-tailed t-test. Data is represented as box and whiskers graph or bar graphs 
(representing mean ± standard deviation). Prism 6 (GraphPad Software) was used for data 
analyses and generation of graphs.  
 
Discussion 
Because of significant decline in HIV-related morbidity since the introduction of HAART, liver 
disease caused by chronic HCV infection has emerged as a major problem in HIV-1/HCV co-
infected individuals. HIV co-infection has a negative impact on HCV pathogenesis, and therefore 
it is recommended to control HIV-1 levels prior to beginning HCV treatment in co-infected 
individuals. It is also important to note that despite successful response to HAART, many 
individuals fail to achieve full functional restoration of their immune system. If such individuals 
get infected with HCV, their ability to mount a successful immune response against HCV could 
be compromised. HIV-1/HCV co-infection should thus be considered a pathological state with 
both unique and common features of HIV-1 and HCV mono-infection. Although our immune 
response can clear HCV30, virus exposure often proceeds to chronicity. PEG-IFN and RBV 
combination therapy has been the mainstay of HCV treatment. IFN is a potent antiviral cytokine 
but is very unpleasant for the patient because of significant side effects such as depression, 
anemia, thrombocytopenia, neutropenia, diarrhea, and flulike symptoms such as fever, chills,   
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Figure 2.5: Increased PD-L1/CD86 ratio on pDCs of NRs before and after IFN/RBV 
treatment. PBMCs isolated from seronegative controls, NRs and SVRs were stained with 
polychromatic antibody cocktail described in supplementary Fig. 1. (A) PD-L1/CD86 ratio on 
mDCs (calculated by dividing the percentage of mDCs expressing PD-L1 by the percentage of 
mDCs expressing CD86) of seronegative controls, NRs and SVRs before and after IFN/RBV 
treatment, (B) PD-L1/CD86 ratio on pDCs of seronegative controls, NRs and SVRs before and 
after IFN/RBV treatment. P values were calculated using Student’s t test (* represents P<0.05). 
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fatigue, headache, and muscle aches. Besides, in individuals infected with the difficult-to-treat 
HCV genotypes (genotypes 1 and 4), it is curative only 40–50% of the time. Although first-
generation direct-acting antiviral drugs are now being introduced into the clinic, high cost and 
emergence of drug resistant HCV variants remain important concerns. IFN/RBV will thus be an 
essential part of HCV treatment and therefore a thorough understanding of its mechanism of 
action is necessary in order to identify host factors that predictive IFN/RBV treatment response. 
Genome-wide association studies have identified SNPs near IFNL3 locus that can predict 
both spontaneous HCV clearance26,31 and successful clinical outcome to HCV therapy31-34. These 
SNPs associate with altered mRNA expression of IFNL3, an antiviral cytokine, suggesting that 
IFNL3 expression levels are associated with HCV clearance and response to therapy32,33,35. 
Interestingly, SNPs in the IFNL3 locus have been shown to affect the expression of IFNL3 not 
only in liver which is the site of infection but in PBMCs and whole blood32,33,35-37 with the minor 
(unfavorable) allele resulting in less IFNL3 expression. Interestingly, unfavorable IFNL3 
genotype has been shown to influence DC and NK cells29,38.  
Recent studies have led to identification of two functional SNPs rs4803217 and 
ss469415590 that are associated with both natural and treatment-based clearance of HCV27,28,39-
41. In our study, we did not observe any correlation between rs12979860, rs4803217 and 
ss469415590 genotypes and DC functionality (Fig. 2.1B-E), however it will be interesting to 
study how different IFNL3 polymorphisms affect IFNL3 expression and resulting induction of 
Interferon-stimulated genes (ISGs) in DCs. It is possible that IFNL3 polymorphisms are 
responsible for intrinsic defects in DCs and thus responsible for generation of attenuated antiviral 
immune response.  
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The importance of DCs in resolving viral infection has been shown for several viruses 
including HIV-1 and HCV. Individuals that can control HIV-1 and HCV infection are 
characterized by strong multi epitope-specific CD4+ and CD8+ T cell response probably 
reflecting the efficient antigen presentation and T cell activation potential of DCs42-45. However, 
chances of viral clearance after HCV and HIV-1 infection are low, owing to the remarkable 
ability of these viruses to impair DC functions. At the primary level, viruses can modulate the 
frequency of various DC subsets by causing their aberrant trafficking, inducing apoptosis, or 
interfering with their development. Compared to uninfected individuals, HIV-infected18-21,46,47 
and HCV-infected12,23-25,48,49 individuals have lower frequency of mDCs and pDCs in blood. 
During HIV-1 infection, pDCs migrate to the inflamed lymph nodes, where they become 
activated, apoptotic, and frequently infected with the virus50,51. During HCV infection, blood 
DCs are enriched in liver25,52-54 suggesting that increased migration of DCs to liver, the primary 
site of HCV replication, could be the cause of observed drop in DC numbers in blood. Other 
possibilities are that HCV targets DC precursors55, or differentiated DCs. In this regard, it has 
been shown that HCV core, NS3, and NS5 proteins induce apoptosis in mature DCs56. Our 
results show that the frequency of mDCs was diminished in NRs (Fig. 2.2A) whereas the 
frequency of pDCs was diminished in both NRs and SVRs (although to a greater extent in NRs) 
(Fig. 2.2B). It is worth noting that HCV-infected individuals with high intrahepatic expression of 
ISGs prior to treatment achieve the lowest therapy response rates35,57,58. Since HCV has evolved 
a potent strategy to preclude IFN production by infected hepatocytes, the cellular source of IFN 
responsible for inducing these ISGs in NRs has been unknown for a long time. Recent studies 
have solved this conundrum by demonstrating the ability of HCV-infected cells to release HCV 
RNA containing exosomes, which upon recognition by hepatic pDCs trigger IFN production59.  
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Figure 2.6: Higher frequency of CCR5+ mDCs in HIV-1/HCV co-infected individuals, but 
they are downregulated in response to treatment. PBMCs isolated from seronegative controls, 
NRs and SVRs were stained with polychromatic antibody cocktail described in supplementary 
Fig. 1. (A) Box and whiskers graph indicating the percentage of mDCs expressing CCR5 in NRs, 
and (B) SVRs prior to and during the course of IFN/RBV treatment. (C) Box and whiskers graph 
indicating the percentage of pDCs expressing CCR5 in NRs, and (D) SVRs prior to and during 
the course of IFN/RBV treatment. P values were calculated using Student’s t test (* represents 
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Figure 2.7: SVRs secrete higher amounts of IFN-γ  before IFN/RBV treatment, whereas 
NRs secrete higher amounts of IFN-γ  after IFN/RBV treatment. PBMCs from seronegative 
controls, NRs and SVRs were cultured for 18h and levels of various Th1/Th2/Th17 cytokines 
were measured using Human Th1/Th2/Th17 Cytokine array (SA Biosciences, Qiagen). (A) Bar 
graph indicating the concentration of IFN-γ secreted by PBMCs (during 18h culture) of controls, 
NRs and SVRs isolated at week 0, and (B) week 48 of treatment. P values were calculated using 
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Therefore, it may be possible that in NRs, the increased expression of ISGs is due to greater 
frequency/IFN production of pDCs within liver. In fact our results show that prior to treatment, 
NRs had higher frequency of CCR5+ pDCs (Fig. 2.6B and 2.6C), which could be responsible for 
their increased migration to liver, the site of inflammation. Upon IFN/RBV treatment, the mDC 
frequency increased in NRs (Fig. 2.2C) but remained unchanged in SVRs (Fig. 2.2D). On the 
other hand, the frequency of pDCs reduced even further in NRs (Fig. 2.2E) but remained 
unchanged in SVRs (Fig. 2.2F). HIV-1 is known to infect mDCs60; therefore we were interested 
in investigating whether mDCs in NRs serve as HIV-1 reservoir and thus become functionally 
compromised. We did not detect any differences in the frequency of CD4+CCR5+ mDCs 
between NRs and SVRs (data not shown).  
In addition to direct antiviral effects, IFN-α is recognized to play an important role in 
regulation of innate and adaptive immune responses. Immunomodulatory effects of IFN-α are 
partly mediated through their ability to regulate maturation, migratory potential and 
immunostimulatory capacity of DCs61-64. Differential IFN signaling in DCs of NRs and SVRs 
could underlie intrinsic differences in modulation of DC functions during treatment. Many 
studies on HCV-infected individuals have shown that various phenotypic and functional 
characteristics of DCs associate with the treatment outcome. High CD83 expression and low IL-
10 production of DCs8,65 as well as lower chemotaxis index of pDCs to CXCL12 and 
CXCL1066,67 prior to therapy are all associated with SVR. Increased frequency of CD86+ mDCs 
and pDCs upon treatment is also associated with SVR68. All these studies suggest that there is a 
strong link between DC functionality (before or during treatment) and treatment outcome in 
HCV mono-infected individuals. But not many studies have investigated the same in HIV-
1/HCV co-infected individuals. We show that the frequency of mDCs increased during treatment 
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in NRs. This is interesting given the fact that the frequency of CCR7+ mDCs was reduced in NRs 
(Fig. 2.3A). Reduced frequency of CCR7+ mDCs could lead to their reduced migration to lymph 
node resulting in their accumulation in blood. Frequencies of CD54+ and CD62L+ mDCs were 
reduced in both NRs and SVRs (Fig. 2.4) indicating that HIV-1/HCV co-infection impairs the 
maturation potential of mDCs, which fails to recover even after treatment. Also, NRs exhibited 
reduced frequency of CCR7+ pDCs. Our cocktail also included HLA-ABC and HLA-DR but we 
did not observe any differences in HLA-ABC and HLA-DR expression (data not shown). 
Loss of T cell polyfunctionality T is one of the major events during the establishment of 
persistent viral infection10,69. Binding of PD-L1 (on DCs) to PD-1 (on T cells) delivers a 
coinhibitory signal to T cells leading to their reduced proliferation and effector functions. Our 
study shows that NRs to IFN/RBV treatment have higher pDC PD-L1/CD86 ratio (Fig. 2.5), 
which could be the cause of failed treatment response. Many viruses are known to attenuate the 
antiviral immune response by upregulating PD-1/PD-L1 expression. PD-1/PD-L1 blockade has 
shown tremendous promise in restoring the antiviral immune response against many different 
viruses. In future, it will be important to learn about the exact mechanisms of PD-L1/PD-1 
upregulation during chronic viral infections. We also show that prior to treatment, PBMCs from 
SVRs secrete higher amounts of IFN-γ compared to controls and NRs (Fig. 2.7). IFN-γ, a Th1 
cytokine plays an important immunoregulatory role by enhancing the cytotoxic activity of T 
cells, macrophages and NK cells. Interestingly, IFN-γ levels secreted by PBMCs drop in SVRs at 
the end of treatment suggesting that infection of PBMCs in SVRs (and not NRs) could be the 
cause of high pre-treatment levels of IFN-γ and thus could be an important predictor of treatment 
success. Overall, this study emphasizes the role of DCs in mediating treatment induced clearance 
of HCV. It also supports the possibility of using DC-based immunotherapeutic strategies. 
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Identification of Interferon-stimulated genes signature in peripheral 

















Although high pre-treatment expression of ISGs in liver is a good predictor of poor response to 
IFN/RBV treatment, there is no clear consensus regarding the correlation between ISGs 
expression in PBMCs and treatment outcome. In this study, we compared the expression of 
forty-six ISGs between NRs and SVRs both before and at week 4 of IFN/RBV treatment. We 
found that the pre-treatment levels of sixteen ISGs were moderately higher in SVRs compared to 
NRs. At week 4 of IFN/RBV treatment, nineteen ISGs were upregulated and fifteen ISGs were 
downregulated in SVRs. Next, we identified miRNAs whose expression can be regulated by 
IFN-α in PBMCs. miR-155 was one of the many miRNAs upregulated by IFN-α and its 
expression varied between NRs and SVRs both before and at week 4 of treatment. Overall, our 



















Recognizing the presence of invading pathogens is an important first step in mounting an 
effective innate immune response. For this purpose, mammalian cells pattern recognition 
receptors (PRRs) that bind to a variety of pathogen associated molecular patterns (PAMPs) 
displayed by viruses, bacteria, fungi and many other pathogens. These receptors can be 
cytoplasmic, e.g. retinoic inducible gene-I (RIG-I)-like receptors (RLRs) and NOD-like 
receptors (NLRs), or endosomal, e.g. Toll-like receptors (TLRs) (Blasius et al., 2010; Kawai et 
al., 2011). Upon PAMP engagement, PRRs trigger intracellular signaling cascades resulting in 
production of type I interferons (IFN-I) pre-dominantly IFN-α/β. IFN-I bind to heterodimeric 
transmembrane receptor known as IFN-α receptor (IFNAR) ubiquitously expressed on the 
surface of target cells. Upon IFN-α/β engagement, IFNAR activates the Janus kinase (JAK)-
signal transducer and activator of transcription (STAT) pathway leading to transcription of IFN-
stimulated genes (ISGs) with diverse antiviral effector functions9-16. It has been shown that 
PRR signaling (specifically by mitochondrial antiviral signaling protein MAVS) is required for 
functional innate and adaptive responses during West Nile virus (a related virus of the 
Flaviviridae family) infection. Importantly, HCV has evolved strategies to preclude IFN-I 
induction by infected hepatocytes (Cheng et al., 2006; Liang et al., 2008). Specifically, HCV 
NS3-4A protease proteolytically cleaves MAVS, which is an important signaling adapter in the 
RLR sensing pathway (Foy et al., 2005; Horner et al., 2011; Li et al., 2005b; Loo et al., 2006; 
Meylan et al., 2005). NS3-4A also cleaves the TIR-domain-containing adapter-inducing IFNβ 
(TRIF) adapter thus abrogating signaling transduction induced by endosomal TLR3 (Li et al., 
2005a; Wang et al., 2009). Despite these inhibitory mechanisms, HCV infection strongly triggers 
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the expression of ISGs in HCV infected individuals (Alter et al., 2000). Recent studies have 
demonstrated that infected hepatocytes can transfer HCV RNA to liver resident/infiltrating 
pDCs, which then produce IFN-α and induce the expression of these ISGs.  
It is widely accepted that high expression of ISGs in liver prior to IFN/RBV treatment 
associates with poor response to therapy. Since access to liver biopsies from HCV-infected 
individuals is difficult, identification of ISGs signature in PBMCs that helps predict the treatment 
outcome will greatly enable effective clinical management of HCV. Although few studies have 
studied ISGs expression in PBMCs of HCV-infected individuals on IFN/RBV treatment, the 
results have been inconclusive so far. Also, ISGs expression in PBMCs of HIV-1/HCV co-
infected individuals is relatively less studied compared to HIV-1 and HCV mono-infected 
individuals. This is an important factor since HIV-1 is known to induce ISGs expression and 
therefore differential expression of ISGs in NRs and SVRs could be influenced by their HIV-1 
levels in periphery. In this study, we compared the expression of forty-six ISGs between NRs 
and SVRs both before and at week 4 of IFN/RBV treatment. We found that the pre-treatment 
levels of sixteen ISGs were moderately higher in SVRs compared to NRs. At week 4, nineteen 
ISGs were upregulated and fifteen ISGs were downregulated in SVRs.  
IFN-α has been shown to exert its antiviral and immunomodulatory effects through 
modulation of miRNAs1. We hypothesized that differential expression of IFN-regulated miRNAs 
in PBMCs of NRs and SVRs could be responsible for differences in their response to IFN/RBV 
treatment. For that we first identified miRNAs whose expression can be regulated by IFN-α in 
PBMCs. miR-155 was one of the many miRNAs upregulated by IFN-α and its expression varied 
between NRs and SVRs both before and at week 4 of treatment. Overall, our results indicate that 
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lower miR-155 expression and higher levels of ISGs could be predictive of treatment success 
 
Results 
Higher pre-treatment ISGs expression in SVRs  
Although high pre-treatment expression of ISGs in liver is a good predictor of poor response to 
IFN/RBV treatment, there is no clear consensus regarding the correlation between ISGs 
expression in PBMCs and treatment outcome2-4. Our study shows that pre-treatment frequency of 
pDCs is reduced in NRs and it is further reduced during IFN/RBV treatment. pDCs are the most 
potent producers of IFN-α and therefore it will not be unreasonable to believe that NRs, owing to 
their reduced frequency of IFN-α producing pDCs, have lower expression of ISGs in PBMCs. 
Many of the ISGs play a critical role in bridging the innate and adaptive antiviral immune 
response. High pre-treatment HCV RNA levels in serum are predictive of poor treatment 
response. It is possible that lower ISGs expression in PBMCs is responsible for inefficient 
immune response against HCV especially during the acute phase of infection. In our study, we 
compared the pre-treatment levels of forty-six ISGs in NRs and SVRs. The cut-off for significant 
fold upregulation/downregulation was set to 1.5. We found that thirty of the forty-six ISGs did 
not show much difference in their expression between NRs and SVRs (Fig. 3.1A). Expression of 
remaining sixteen ISGs was moderately higher in SVRs compared to NRs (Fig. 3.1B). Some of 
the upregulated ISGs such as ADAR, MX1, OAS1 and IFIT3 are known to possess anti-HCV 
activity and therefore higher pre-treatment levels of these potent anti-HCV ISGs could be a good 








ISGs expression at week 4 of IFN/RBV therapy helps predict the treatment response 
After investigating the pre-treatment levels of ISGs, we studied their regulation after first four 
weeks of IFN/RBV treatment. We observed that ten ISGs had no difference in expression 
between NRs and SVRs. Out of these ten ISGs, five ISGs (indicated as orange bars, fig. 3.2A) 
had no difference in expression at week 0 as well. Twenty-two ISGs were upregulated in SVRs 
out of which only three ISGs (indicated as orange bars, fig. 3.2B) were already high at week 0. 
Fifteen ISGs were downregulated in SVRs at week 4 and none of those ISGs were 
downregulated at week 0 (indicated by absence of orange bars, fig. 3.2C). Interestingly, two of 
these fifteen ISGs, ADAR and IFIT3 are known to possess anti-HCV activity. Overall, we 
identify nineteen ISGs that are upregulated and fifteen ISGs that are downregulated in SVRs 
after four weeks of IFN/RBV treatment. It will be interesting to study the mechanisms through 
which some of these ISGs could affect the treatment outcome. 
 
Identification of IFN-α  modulated miRNAs in PBMCs of healthy donors 
While IFN-α has been shown to regulate the expression of several mRNAs, its effect on miRNA 
expression needs more attention. MicroRNAs (miRNAs), an important class of post-
transcriptional regulators of gene expression, have emerged as crucial players in regulation of 
innate and adaptive immune responses, and their abnormal expression and/or function in the 
immune system has been linked to several pathological states. IFN-α has been shown to induce 
miR-1, miR-30, miR-125, miR-142, miR-196, miR-296 and miR-351 in Huh7 cells1. These 
miRNAs have seed sequence complementarity to HCV RNA and can suppress HCV replication1. 








Figure 3.1: Higher pre-treatment ISGs expression in SVRs. PBMCs from NRs and SVRs at 
week 0 of IFN/RBV treatment were used to prepare cell lysate (for qPCR based profiling of ISGs 
expression using Power SYBR Green Cells-to-CT kit and human type I Interferon response 
qPCR array). Cell lysates from six NRs and SVRs were pooled for qPCR. (A) Bar graph 
indicating ISGs whose expression was <1.5-fold higher/lower in SVRs compared to NRs. (B) 















































































four miRNAs that are differentially expressed in various immunopathological states and 
investigate whether their expression in PBMCs in healthy donors is modulated by IFN-α. The 
cut-off for significant fold upregulation/downregulation was set to 1.5. We found that out of 
eighty-four miRNAs, thirty-one miRNAs were upregulated (Fig. 3.3A) and thirty-three were 
downregulated (Fig. 3.3B), whereas expression of remaining twenty miRNAs did not change 
significantly. Importantly our results show that miR-30, miR-125 and miR-142, which are 
validated IFN-α-induced miRNAs in Huh7 cells1, are IFN-α-inducible in PBMCs as well. 
 
Differential expression of miR-155 in SVRs and NRs 
Our next step was to investigate whether above identified IFN-α modulated miRNAs are 
differentially expressed in NRs and SVRs before and during IFN/RBV treatment. We performed 
thorough literature search in order to identify IFN modulated miRNAs (from our results) that 
were experimentally validated to target ISGs investigated in our study. This led to identification 
of miR-155-SOCS1 pair for further investigation1. Our study shows that IFN-α upregulates miR-
155 expression in PBMCs. TLR signals such as TLR2, TLR3, TLR4, and TLR9 are also known 
to upregulate miR-1555,6. Its upregulation is associated with pro-inflammatory cytokine response 
owing to its ability to target suppressor of cytokine signaling (SOCS1). Since NRs are 
characterized by presence of higher HCV RNA levels in serum, we investigated whether miR-
155 expression was higher in NRs as compared to SVRs. To this end, we measured the 
expression of both miR-155 and its target SOCS1 in six NRs and SVRs. We found that pre-
treatment expression of miR-155 was significantly higher in NRs compared to SVRs (Fig. 3.4A). 
We believe this could be due to both TLR mediated sensing of HCV by peripheral immune cells 
such as macrophages and DCs as well as by endogenous IFN secreted by pDCs. By week 4 of 
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IFN/RBV treatment, HCV RNA levels were significantly reduced in SVRs (data not shown), 
which correlated with reduced miR-155 levels. On the other hand, HCV RNA did not drop 
drastically in NRs and neither did miR-155 levels. Also, SOCS1 expression remained unchanged 
in NRs, whereas it increased significantly in SVRs. 
 
Materials and Methods 
Clinical samples. A total of twelve HCV/HIV-1 co-infected, PEG-IFN-a/RBV treatment naïve 
patients recruited from the Hepatitis Clinic of New York/Weill/Cornell Medical Center in a 
cohort study were used. The study design was approved by the Institutional Review Board of 
Weill Medical College of Cornell University and conforms to the 1975 Helsinki guidelines for 
the conduct of human research. Inclusion criteria, as described previously, required that patients 
have detectable HCV RNA, be on a stable course of antiretroviral therapy or no antiretroviral 
agents for at least four weeks prior to pegylatedinterferon/ RBV initiation, and to have a CD4+ 
T-cell count ≥ 100 cells/mm3. Patients were excluded if they had severe depression, 
immunodeficiency-related opportunistic infections, on active substance abuse, or were pregnant 
or lactating. Subjects were treated with 1.5 mg/kg of PEG-INTRON (Schering Plough, 
Kenilworth, NJ) once weekly and a 1000-1200 mg total daily dose of RBV (Rebitrol, Schering 
Plough), taken every 12 hrs for up to 48 weeks. Patients with HCV RNA below detection limit 
(<29 IU/ml) 24 weeks after treatment cessation are referred to as SVRs. This study investigated 














MX1 Unknown 7 
MX2 Unknown 8 
ISG20 Exonuclease activity  9 
IFITM1 Inhibits receptor-
mediate HCV entry 
10-12 
IFITM3 Intracellular 
trafficking of HCV 
10,13,14 
OAS1 Activates RNase I 7 









Isolation of PBMCs. PBMCs were isolated from healthy donors (Biological Specialty 
Corporation, Colmar, PA) by density gradient centrifugation using Ficoll Paque Plus (GE 
Healthcare Life Sciences, Piscataway, NJ). After isolation, they were washed with DPBS 
(without calcium and magnesium) and cleared of contaminating red blood cells using ACK lysis 
buffer (Quality Biological, Gaithersburg, MD). PBMCs were washed two additional times and 
rested for 1 hour before treating them with IFN-α.  
 
miRNA expression profiling in PBMCs treated with IFN-α . PBMCs were treated with IFN-α 
(2000 U/ml) for 24h. After treatment, total RNA including miRNA was isolated using the 
miRNeasy Mini kit (Qiagen, Valencia, CA) and miRNA expression profiling was performed 
using qPCR. cDNA required for qPCR was generated using miScript II RT Kit (SA Biosciences, 
Qiagen). Human Immunopathology miScript miRNA PCR Array (MIHS-104Z, SA Biosciences) 
consisting of pre-designed forward primers (corresponding to each miRNA) was used to profile 
the expression of 84 miRNAs known to be differentially expressed in various 
immunopathological states. miScript SYBR Green PCR Kit (SA Biosciences) was used for 
amplifying cDNA during qPCR. RNU6-2 was used as normalization control in order to calculate 
fold change between untreated and treated cells. Roche LightCycler 480 Instrument II was used 
for all qPCR reactions. For measuring the expression of miR-155 in figure 4, TaqMan miRNA 










Figure 2: ISGs expression at week 4 of IFN/RBV therapy helps predict the treatment 
response. PBMCs from NRs and SVRs at week 4 of IFN/RBV treatment were used to prepare 
cell lysate (for qPCR based profiling of ISGs expression using Power SYBR Green Cells-to-CT 
kit and human type I Interferon response qPCR array). Cell lysates from six NRs and SVRs were 
pooled for qPCR. (A) Bar graph indicating ISGs whose expression was <1.5-fold higher/lower in 
SVRs compared to NRs. (B) Bar graph indicating ISGs whose expression was >1.5-fold higher 
in SVRs compared to NRs. (C) Bar graph indicating ISGs whose expression was >1.5-fold lower 
















































































Expression profiling of ISGs in PBMCs of NRs and SVRs. PBMCs from NRs and SVRs at 
week 0 and week 4 of IFN/RBV treatment were used to prepare cell lysate for qPCR based 
profiling of ISGs expression using Power SYBR Green Cells-to-CT kit (Ambion) and human 
type I Interferon response qPCR array (SA Biosciences). Quantitect reverse transcription kit 
(Qiagen) was used to make cDNA and Quantitect SYBR green PCR master mix (Qiagen) was 
used to amplify DNA during qPCR. For measuring the expression of SOCS1 in figure 4, same 
reagents were used except the forward and reverse primers that were designed by us. 
 
Statistical Analysis. Statistical significance was determined by Student's two-tailed t-test or. 
Error bars represent the means ± standard deviation (SD). Data were analyzed and graphs were 
generated using Prism 6 (GraphPad Software). 
 
Discussion 
Both innate and adaptive arms of immunity play an important role in host’s ability to resolve 
HCV infection. Cross talk between liver-resident and infiltrating cells (such as hepatocytes, 
kupffer cells, hepatic stellate cells, pDCs, NK cells and other immune cells) is critical for 
generation of protective immunity against HCV. HCV has evolved mechanisms to evade these 
immune responses by interfering with its detection in the infected hepatocytes. Impaired 
intracellular innate immune signaling leads to dysfunctional adaptive immune response resulting 
in chronic infection in majority of acutely infected individuals. Although high pre-treatment 
expression of ISGs in liver is a good predictor of poor response to IFN/RBV treatment, there is 
no clear consensus regarding the correlation between ISGs expression in PBMCs and treatment 
outcome2-4. Our study has showed that pre-treatment frequency of pDCs is reduced in NRs and it 
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is further reduced during IFN/RBV treatment. pDCs are the most potent producers of IFN-α and 
therefore it will not be unreasonable to believe that NRs, owing to their reduced frequency of 
IFN-α producing pDCs, have lower expression of ISGs in PBMCs. Many of the ISGs play a 
critical role in bridging the innate and adaptive antiviral immune response. High pre-treatment 
HCV RNA levels in serum are predictive of poor treatment response. It is possible that lower 
ISGs expression in PBMCs is responsible for inefficient immune response against HCV 
especially during the acute phase of infection. Our study shows that the expression of sixteen 
ISGs was moderately higher in SVRs compared to NRs (Fig. 3.1B). Some of the upregulated 
ISGs such as ADAR, MX1, OAS1 and IFIT3 are known to possess anti-HCV activity (table 3.1) 
and therefore higher pre-treatment levels of these potent anti-HCV ISGs could be a good 
predictor of treatment success. Also, SVRs had higher pre-treatment STAT2 levels suggested by 
another study as well16. STAT2 forms a complex with STAT1 and IRF9, which induces the 
expression of many ISGs. Therefore, higher levels of STAT2 in SVRs could be reflective of 
heightened IFN signaling at week 0 as well as higher responsiveness to exogenously 
administered IFN as evidenced by increase in a significant number of ISGs at week 4. There are 
thousands of ISGs and many of them have unknown functions. We believe that one should adopt 
a targeted approach to select only those ISGs for predicting the treatment outcome whose 
function in clearing HCV is known. We also identified nineteen ISGs that were upregulated and 
fifteen ISGs that were downregulated in SVRs after four weeks of IFN/RBV treatment (Fig. 3.2). 
One of the downregulated ISG was CXCL10, a chemokine. Interestingly, our finding is 
corroborated by another study that measured CXCL10 levels in plasma of 29 HCV-infected 
individuals before, during and after IFN/RBV therapy showed that the levels of CXCL10 
decreased following successful antiviral therapy17. It will be interesting to study the mechanisms 
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Figure 3: Identification of IFN-α  modulated miRNAs in PBMCs of healthy donors. PBMCs 
isolated from one healthy donor were exposed to IFN-α for 24 hours. Following treatment, total 
RNA including miRNA was isolated using miRNeasy mini kit and expression of 84 miRNAs 
known to be differentially expressed in various immunopathological states was profiled using 

















































































through which some of these ISGs could affect the treatment outcome. 
 MicroRNAs are potent regulators of gene expression. Pedersen et al showed that IFN-β  
induces the expression of seven miRNAs (miR-1, miR-30, miR-125, miR-142, miR-196, miR- 
296 and miR-351) in Huh7 cells. These miRNAs directly bind to HCV RNA and repress its  
replication. This shows that RNA interference as a means to control viral replication exists in 
mammals. But besides this, various studies have shown that miRNAs can control various aspects 
of our immune system such as TLR responsiveness, cytokine signaling, maturation of DCs and 
macrophages. It is believed that IFNs can exert their antiviral and immunomodulatory effects by 
modulating miRNAs. Our results indicate that three (miR-30, miR-125, miR-142) of the seven  
miRNAs are IFN-inducible in PBMCs as well (Fig. 3.3). Since HCV infects PBMCs, although to 
a lower extent compared to hepatocytes, it will be interesting to investigate whether these three 
miRNAs are capable of controlling HCV replication in PBMCs. We also show for the first time 
that IFN-α can upregulate miR-155 expression in PBMCs. Earlier studies have demonstrated 
miR-155 upregulation in macrophages and DCs in response to TLR signals and IFN-I5,6. miR-
155 upregulation is associated with pro-inflammatory cytokine response owing to its ability to 
target SOCS1. Since NRs are characterized by presence of higher HCV RNA levels in serum, we 
investigated whether miR-155 expression was higher in NRs as compared to SVRs. We found 
that pre-treatment expression of miR-155 was significantly higher in NRs compared to SVRs 
(Fig. 3.4A). This could be due to both TLR mediated sensing of HCV by peripheral immune 
cells such as macrophages and DCs and/or endogenous IFN secreted by pDCs, however if we 
keep our previous study (Chapter 2 which shows a significant reduction in frequency of pDCs in 
NRs compared to SVRs) into consideration, high IFN-α levels in blood as a cause of increased 
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miR-155 expression is not a valid argument. However, there are other studies that show no 
differences in pDC frequency and their IFN production between NRs and SVRs. Overall, HCV 
RNA is more plausible cause of miR-155 upregulation in NRs. More thorough studies should 
explore this argument. By week 4 of IFN/RBV treatment, HCV RNA levels were significantly 
reduced in SVRs (data not shown), which correlated with reduced miR-155 levels. On the other 
hand, HCV RNA did not drop drastically in NRs and neither did miR-155 levels. Also, SOCS1 
expression remained unchanged in NRs, whereas it increased significantly in SVRs. Collectively, 
we were able to demonstrate the correlation between ISGs expression and miR-155 expression in 
PBMCs and response to PEG-IFN/RBV treatment. We are confident that this work will prove to 
be beneficial for both diagnostic purposes and for understanding the modulation of type I IFN 


















Figure 4: Differential expression of miR-155 in SVRs and NRs. PBMCs from NRs and SVRs 
at week 0 and week 4 of IFN/RBV treatment were used to prepare cell lysate (for qPCR based 
profiling of miRNA and mRNA expression. (A) Bar graph indicating miR-155 expression in 
NRs (n=6) and SVRs (n=6) at week 0 and week 4 of IFN/RBV treatment. (A) Bar graph 
indicating SOCS1 expression in NRs (n=6) and SVRs (n=6) at week 0 and week 4 of IFN/RBV 
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IFN-α-induced downregulation of miR-221 in dendritic cells: 


















Abstract    
Besides their well-appreciated role in direct antiviral defense, IFN-α plays a critical role in the 
regulation of innate and adaptive immune response. Immunomodulatory properties of IFN-α are 
facilitated by its action on dendritic cells (DCs), professional antigen presenting cells critical to 
generation of protective immunity. Various microRNAs are known to regulate DC functions but 
it remains unclear whether IFN-α exerts its effects on DCs through miRNAs. In this study, we 
examined miRNA expression patterns in myeloid and plasmacytoid DCs in response to IFN-α 
and observed miR-221 downregulation via IFN induced STAT3 inhibition in both. Using in 
silico approaches followed by experimental validation, CDKN1C, CD54 and SOCS1 were 
identified as miR-221 targets. Moreover, miR-221 overexpression in mDCs enhanced their 
secretion of proinflammatory cytokines IL-6 and IFN-α but reduced the secretion of anti-
inflammatory cytokine IL-10. In PBMCs isolated from HIV-1/HCV co-infected patients on 
standard IFN-α therapy, pre-treatment levels of miR-221 were significantly lower in non-
responders compared to responders and healthy controls. Also, in patients PBMCs, miR-221 and 
CDKN1C, CD54, IL-6 and TNF-α levels correlated similarly as observed earlier in mDCs. In 
addition, we isolated total liver cells and kupffer cells (antigen presenting cells in liver) from 
HCV infected individuals as well as individuals with alcoholic cirrhosis. We found that both 
total liver cells and kupffer cells from HCV-infected individuals had significantly higher miR-
221 levels compared to cirrhotic patients. Overall, this study demonstrates a role of IFN-α/miR-











Mammalian cells are equipped with several classes of pattern recognition receptors (PRRs) to 
recognize and mount a potent immune response against pathogens1. Upon engagement with 
pathogen-associated molecular patterns (PAMPs), PRRs trigger intracellular signaling cascades 
resulting in production of type I interferons (IFN-I). Most cell types produce IFN-β upon 
encountering pathogens, whereas hematopoietic cells, particularly plasmacytoid dendritic cells 
(pDCs) are major producers of IFN-α2-4. IFN-α/β binds to a ubiquitously expressed 
heterodimeric transmembrane receptor, known as IFN-α receptor (IFNAR), and activates Janus 
kinase (JAK)-signal transducer and activator of transcription (STAT) pathway ultimately leading 
to transcription of IFN-stimulated genes (ISGs) that possess diverse antiviral functions5-7. 
In addition to direct antiviral effects, IFN-I are recognized to play an important role in 
regulation of innate and adaptive immune responses. Immunomodulatory effects of IFN-I are 
partly mediated through their ability to regulate maturation, migratory potential and 
immunostimulatory capacity of DCs, in particular myeloid DCs, mDCs8-11. Optimal DC 
functionality is a crucial requirement for successful resolution of persistent viral infections such 
as HIV-1 and HCV12, 13, and a thorough understanding of molecular mechanisms that shape DC 
functions is of paramount importance.  
In addition to protein coding genes, IFN-I can regulate the expression of microRNAs 
(miRNAs) in various cell types14-21 including those associated with the innate and adaptive 
immune system22-24. miRNAs act as posttranscriptional regulators of gene expression by binding 
to and degrading/translationally repressing their target mRNAs25. It is becoming increasingly 
evident that miRNAs have profound effects on DC functions such as activation, maturation, 
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cytokine secretion and antigen presentation19, 26-33, however it is not completely understood 
whether IFN-I exert their immunomodulatory effects on DCs through modulation of miRNAs.  
In this study we analyzed changes in expression of ~120 mature miRNAs after exposure 
of mDCs and pDCs to IFN-α. These miRNAs were curated based on experimentally validated 
(or potential) capacity to regulate DC function. From this analysis, we identified miR-221 as 
potently downregulated by IFN-α in both DC subsets We validated CD54 as miR-221 target in 
mDCs and demonstrate that mDCs of HIV-1/HCV co-infected individuals who successfully 
clear HCV following IFN/Ribavirin therapy (sustained virological responders; SVRs) have 
higher CD54 expression compared to non-responders (NRs). This suggests that HCV may be 
able to interfere with IFN-mediated regulation of miR-221 in non-responders. Overall this study 
has, for the first time, demonstrated the role of IFN-miRNA axis in controlling DC functions.  
 
Results 
IFN-α induces downregulation of miR-221-3p in DCs 
In order to determine if IFN-α can regulate the expression of miRNAs in DCs, we used a 
targeted approach using a library of 113 miRNAs consisting of most abundantly expressed and 
best-characterized miRNAs in miRBase (Supplementary table 4.1), as well as miRNAs 
associated with innate immunity and DC functions (Supplementary table 4.2). mDCs were 
treated with a standard dose (2000 U/ml) of IFN-α-2a for 24h, and miRNAs were profiled using 
miScript miRNA qPCR assay (SA Biosciences). Fold-change was calculated using two small 
nucleolar RNAs SNORD68 and SNORD95 as normalization controls, and a cut-off of 1.5-fold 








Figure 4.1: IFN-α induces downregulation of miR-221-3p in DCs. (A) Heat map representing 
fold change in expression of 113 miRNAs (84 miRNAs profiled using Human miFinder miScript 
miRNA qPCR Array, SA Biosciences plus 29 miRNAs whose qPCR primers were designed 
according to similar strategy as miFinder array (Primer sequences mentioned in table 1), in 
mDCs (n=2) upon 24h IFN-α treatment. Asterisk (*) indicates miRNA hits with greater than 1.5 
fold change in both biological replicates. (B) Bar graph indicating the fold change in expression 
of seven potential IFN-regulated miRNAs (miR-7, miR-155, miR-221, miR-23b, miR-124 and 
miR-376c) in mDCs (n=2). (C) Bar graph indicating the fold change in expression of above-
mentioned miRNAs in pDCs upon 24h IFN-α treatment. (D) Bar graph indicating fold change in 
expression of miR-221 in B cells upon 24h IFN-α treatment. (E) Kinetics of IFN-α-induced 
downregulation of miR-221 at 4h, 8h, 12h and 12h post IFN-α treatment. P values were 
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(miR-7-5p, miR-23b-3p, miR-124-3p, miR-155-5p, miR-221-3p, miR-222-3p and miR-376c-3p) 
to be significantly modulated upon IFN-α treatment. The same seven miRNAs were also 
investigated in another DC subset, pDCs, and only miR-221 was found to be significantly 
downregulated in response to IFN-α (Fig. 4.1C). This finding was also confirmed in B cells, 
another important professional antigen presenting cell (Fig. 4.1D). Kinetics studies revealed that 
there was significant downregulation of miR221 as early as 8 h post IFN-treatment, which 
persisted until 24 h (Fig. 4.1E). These studies establish that IFN-α downregulates miR-221 
expression in key immune cell types, including mDCs and pDCs.  
 
IFN-α-induced miR-221 downregulation is mediated by JAK/STAT pathway 
IFN-α activates multiple pathways, including the canonical JAK/STAT signaling pathway, and 
non-canonical signaling cascades such as those involving p38 mitogen-activated protein kinase 
and phosphatidylinositol 3-kinase. To determine if the JAK/STAT pathway is involved in the 
IFN-α-induced downregulation of miR-221, we pretreated mDCs with Ruxolitinib, a small 
molecule JAK1/2 inhibitor34, prior to IFN-α treatment. JAK1/2 inhibition prevented miR-221 
downregulation in response to IFN-α, whereas Ruxolitinib treatment alone had no significant 
effect on miR-221 levels (Fig. 4.2A). We also profiled the mRNA levels of all STAT family 
members and found that IFN-α significantly upregulated STAT1 and STAT4 mRNA in mDCs  
(Fig. 4.2B). Therefore, we were able to establish that IFN-α induced miR-221 downregulation is 








Validation of miR-221 targets and assessment of cytokine secretion profile in miR-221 
overexpressing mDCs 
To more clearly define the role of IFN-α-induced miR-221 downregulation in mDCs, we 
investigated the effect of miR122 loss on known miR-221 targets, BBC3, BCL2L11, BNIP3, 
CDKN1B, CDKN1C, DDIT4, ESR1, FOS, FOXO3, ICAM1, PTEN, TBK1, SOCS1, that are 
already experimentally validated in other cell types (except CDKN1B that is validated in 
monocyte-derived DCs). Cells were transfected with mirVana miR-221 mimic or a negative 
control mimic followed by quantitation of targets 24h post-transfection. Introduction of miR-221 
mimic resulted in downregulation of all but four of the target molecules selected for study, 
including a novel target RIG-I which was identified using bioinformatics approaches (Fig. 4.3A). 
Potential targets that were downregulated up transfection of miR-221 mimic were also validated 
using luciferase reporter construct. BCL2L11, CDKN1C and SOCS1 were validated as miR-221 
targets (Fig. 4.3B). Because miR-221 target SOCS1 is capable of regulating the release of 
various cytokines, we evaluated the Th1/Th2/Th17 cytokine secretion profile of mDCs after 
miR-221 mimic transfection. We found that miR-221 overexpression resulted in higher IL6 and 
TNF-α (Fig. 4.3C). 
 
Role of STAT3 in IFN-α-induced miR-221 downregulation 
STAT3 has been shown to upregulate miR-221 expression in various cancer cells35, 36. In order to 
determine whether IFN-α-induced miR-221 downregulation is mediated by STAT3, we first 








Figure 4.2: IFN-α-induced miR-221 downregulation is mediated by JAK/STAT pathway. 
(A) Bar graph indicating miR-221 fold change in mDCs upon 3h treatment with JAK1/2 
inhibitor, Ruxolitinib (Selleckchem) followed by 24 h IFN-α treatment. The graph shows four 
bars (White: untreated with Ruxolitinib, untreated with IFN-α; Black: untreated with 
Ruxolitinib, but treated with IFN-α; Stripes: treated with Ruxolitinib, but untreated with IFN-α; 
Grey: treated with Ruxolitinib, treated with IFN-α). (B) Bar graph indicating fold change in 
expression of seven STAT family members (STAT1, 2, 3, 4, 5A, 5B and 6) and IKKα in mDCs 
upon 24h IFN-α treatment. P values were calculated using Student’s t test (*P<0.05; **P<0.01). 























































































in response to IFN-α treatment whereas pSTAT1 levels were increased (Fig. 4.4A). We next 
wanted to determine whether IFN-α- induced downregulation of miR-221 is STAT3 dependent. 
For this, we pretreated mDCs with BP-1-102 (A small molecule inhibitor that blocks STAT3 
phosphorylation, dimerization, and DNA-binding activity) prior to IFN-α treatment. 
Interestingly, we found that BP-1-102 treatment alone downregulated miR-221 (Fig. 4B) 
indicating that STAT3 is essential for maintaining steady-state levels of miR-221. Together, the 
data indicate that IFN-α-induced miR-221 downregulation is mediated via STAT3 inactivation. 
Fig. 4C summarizes the mechanism of IFN-α-induced miR-221 downregulation and its effect on 
mDC functions. 
 
Role of miR-221 in IFN/Ribavirin treatment response against HCV 
Thus far, we have established that IFN-α is capable of modulating miR-221 expression in DCs 
through a STAT3 dependent mechanism. In addition, we have validated miR-221 targets 
including CD54, CDKN1C, RIG-I and SOCS-1, and demonstrated that miR-221 overexpression 
induces higher IL6 and TNF-α production in mDCs. Next, we were interested in evaluating how 
IFN-miRNA axis in DCs is affected during chronic infections such as HIV-1 and HCV. miRNAs 
are being increasingly recognized to play an important role in anti-HCV response and clinical 
outcome of standard IFN-based HCV treatment. In light of these observations, we utilized a 
well-characterized cohort of HIV-1/HCV co-infected patients (Table 4.1)) to investigate whether 
miR-221 is differentially regulated in sustained virological responders (SVRs) and non-
responders (NRs) of standard IFN/Ribavirin treatment. First, we determined miR-221 expression 
in peripheral blood mononuclear cells (PBMCs) of seronegative controls, SVRs and NRs 
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isolated at week 0 (baseline) and week 1 of treatment. We found that NRs had lower miR-221 
baseline levels compared to controls (Fig. 4.5A). We also profiled the expression of 84 genes 
associated with IFN response. Out of 84 genes, three genes (CDKN1B, RIG-I and SOCS1) are 
miR-221 targets; therefore we compared the average baseline and week 4 levels in NRs and 
SVRs (Fig. 4.5B). Next, we compared the expression of another miR-221 target, CD54, on 
mDCs. We found that NRs had higher frequency, but not GMFI, of CD54+ mDCs compared to 
controls that correlate with their lower miR-221 levels compared to controls (Fig. 4.5C and 
4.5D). By week 4 of IFN/RBV treatment, both NRs and SVRs had a significant reduction in 
frequency of CD54+ mDCs (Fig. 4.5C) as well as CD54 GMFI (Fig. 4.5D), although the extent 
of downregulation was greater in SVRs. Finally, we evaluated the Th1/Th2/Th17 cytokine 
secretion profile of NRs and SVRs at week 0, early (first four weeks of the 48-week treatment), 
and late (last 2 weeks of the 48-week treatment) and found that SVRs secrete higher amounts of 
IL6 and TNF-α, which is consistent with higher miR-221 levels. Overall, we demonstrate that 
higher miR-221 levels in SVRs correlate with lower CD54 expression and higher IL6 and TNF-
α levels.  
 
Higher miR-221 expression in total liver cells and kupffer cells of HCV-infected individuals 
compared to individuals with alcoholic cirrhosis 
Since liver is the primary site of HCV infection, we investigated miR-221 expression in total 
liver cells as well as kupffer cells, which are major liver-resident antigen presenting cells. We 








Figure 4.3: Validation of miR-221 targets and assessment of cytokine secretion profile in 
miR-221 overexpressing mDCs. (A) mDCs were transfected with mirVana miR-221 mimic or 
negative control mimic. Bar graph indicates fold change in mRNA levels of potential miR-221 
targets in mDCs transfected with miR-221 mimic relative to mDCs transfected with negative 
control mimic. (B) Bar graph indicating the fold reduction in luciferase activity after transfection 
of 3’ UTR-luciferase constructs of BCL2L11, CDKN1C and SOCS1 followed by transfection of 
miR-221 mimic in mDCs (C) Bar graph indicating the concentration (pg/ml) of a panel of twelve 
Th1/Th2/Th17 cytokines secreted by mDCs transfected with negative control mimic (white bar) 
and miR-221 mimic (black bar). P values were calculated using Student’s t test (*P<0.05; 









































































































































chronic HCV infection as compared to individuals compared to individuals with alcoholic 
cirrhosis (Fig. 4.6A). Since our study shows that miR-221 overexpression enhances the secretion 
of pro-inflammatory cytokines IL-6 and TNF-α, higher miR-221 levels in HCV individuals 
could potentially be the cause of inflammation characteristic of chronic HCV infection. Another 
important thing to note is that within both the groups, miR-221 expression is lower in kupffer 
cells compared to total liver cells. We also investigated the responsiveness of cells to in vitro 
IFN-α treatment in terms of miR-221 downregulation and found that total liver cells from both 
the groups were more responsive (although not statistically significant) compared to kupffer 
cells. 
 
Materials and Methods 
Isolation of primary human immune cells. mDCs, pDCs, and B cells were purified from 
PBMCs derived from healthy donors (Biological Specialty Corporation, Colmar PA). Briefly, 
PBMCs were isolated by density gradient centrifugation using Ficoll Paque Plus (GE Healthcare 
Life Sciences, Piscataway, NJ), washed in cell isolation buffer (DPBS without calcium and 
magnesium containing 0.5% BSA and 2mM EDTA) and cleared of contaminating red blood cells 
using ACK lysis buffer (Quality Biological, Gaithersburg, MD). PBMCs were washed two 
additional times prior to purification of (positive selection) and plasmacytoid dendritic cell 
isolation kit II (negative selection) respectively (Miltenyi Biotech, San Diego, CA). B cells were 
isolated in one of the intermittent steps (involving depletion of B cells) during the isolation of 
mDCs. After isolation, 5x105 cells were resuspended in 1 ml AIM-V cell culture media (Life 
technologies) and cultured in 12-well cell culture plates. Cells were always rested for 1 hour 
before proceeding with any experiment. 
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miRNA expression profiling of IFN-α-treated cells. Cells (mDCs, pDCs and B cells) were 
treated with IFN-α (2000 U/ml) for 24h. After treatment, total RNA was isolated using the  
miRNeasy Mini kit (Qiagen, Valencia, CA) and miRNA expression profiling was performed 
using qPCR. cDNA required for qPCR was generated using miScript II RT Kit (SA Biosciences, 
Qiagen). Human miFinder miScript miRNA PCR Array (MIHS-001Z, SA Biosciences) 
consisting of pre-designed forward primers (corresponding to each miRNA) was used to profile 
the expression of 84 most abundantly expressed and best characterized miRNAs in miRBase 
(listed in supplementary table 1). miScript SYBR Green PCR Kit (SA Biosciences) was used for 
amplifying cDNA during qPCR. Profiling of remaining miRNAs investigated in our study (listed 
in supplementary table 2) was performed using the same procedure except that we designed our 
own forward primers (containing the exact sequence as its corresponding miRNA except that the 
‘U’ in mature miRNA sequence is replaced with ‘T’ in forward primer sequence). SNORD68 
and SNORD95 were used as normalization controls in order to calculate fold change between 
untreated and treated cells. Roche Light Cycler 480 Instrument II was used for all qPCR 
reactions. 
 
Inhibition of JAK1/2 and STAT3 activity. To demonstrate that IFN-α downregulates miR-221 
through JAK/STAT signaling, mDCs were pretreated with a selective JAK1/2 inhibitor, 
Ruxolitinib (1µM, Selleckchem) for 3 hours prior to IFN-α treatment. Similarly, STAT3 
dependency of IFN-α-induced miR-221 downregulation was demonstrated by treating cells with  
BP-1-102 (10µM, EMD Millipore) for 2 hours prior to IFN-α treatment. BP-1-102 blocks 
STAT3 phosphorylation, dimerization, and DNA-binding activity. Percentage of DMSO (vehicle  
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Figure 4.4: Role of STAT3 in IFN-α-induced miR-221 downregulation. (A) Freshly isolated 
mDCs were rested for one hour followed by 15-minute IFN-α treatment. After treatment, 
pSTAT3 (pY705)-PE Ab (BD Biosciences) was used to determine pSTAT3 levels by flow 
cytometry. The graph shows control mDCs (untreated with IFN-α) in blue histogram and IFN-α-
treated mDCs in red histogram. Black histogram shows mDCs stained with isotype (IgG-2a κ) 
control Ab. (B) Bar graph indicating miR-221 fold change in mDCs upon 2h treatment with 
STAT3 inhibitor, BP-1-102 (EMD Millipore) followed by 24 h IFN-α treatment. The graph 
shows four bars, White: untreated with BP-1-102, untreated with IFN-α; Black: untreated with 
BP-1-102, but treated with IFN-α; Stripes: treated with BP-1-102, but untreated with IFN-α; 
Grey: treated with BP-1-102, treated with IFN-α. (C) Model figure depicting our findings 
regarding IFN-α-induced miR-221 downregulation and its relevance in mDC functionality. 
Figure shows IFN-α binding to its receptor, IFNAR that results in STAT3 inactivation. STAT3 
is required for maintaining basal levels of miR-221 and therefore its inactivation leads to miR-
221 downregulation. miR-221 targets BCL2L11, CD54, CDKN1C, RIG-I and SOCS1, and 
therefore its downregulation leads to upregulation of its targets. Upregulation of SOCS1 due to 
IFN-α-induced miR-221 downregulation in mDCs leads to decrease in IL-6 and TNF-α 
secretion. P values were calculated using Student’s t test (**P<0.01). Error bars represent 







































































































Figure 4.5: Role of miR-221 in IFN/Ribavirin treatment response against HCV. (A) PBMCs 
were isolated from seronegative controls as well as NRs and SVRs at week 0 (baseline) and 
week 1 of IFN/RBV treatment. Bar graph indicates fold change in miR-221 levels in NRs (grey 
bar) and SVRs (black bar) relative to seronegative controls (white bar). P values were calculated 
using Student’s t test (*P<0.05). Error bars represent standard deviation. (B) PBMCs from week 
0 (baseline) and week 4 of treatment were pooled for both NRs and SVRs and average miR-221 
levels were determined. Bar graph indicates average fold change in miR-221 levels in SVRs 
(grey bar) relative to NRs (white bar). (C) PBMCs from seronegative controls, NRs and SVRs 
were stained with polychromatic flow cytometry Ab cocktail consisting of Lin-1, CD11c, CD123 
and CD54 Abs. Lin-1 was used to gate on DCs and CD11c and CD123 were used to gate on 
mDCs (CD11c+CD123-). Scatter plot indicates the percentage of CD54+ mDCs, and (D) CD54 
GMFI in controls (), NRs () and SVRs () at week 0 and week 4 of treatment. (E) PBMCs 
isolated from NRs and SVRs at week 0 (baseline), early weeks (within first four weeks) and last 
weeks (last four weeks) of treatment were stimulated in-vitro with IFN-α-2a/Ribavirin for 24h, 
and concentrations of a panel of twelve Th1/Th2/Th17 cytokines were determined in culture 
supernatant using ELISA. Scatter plot indicates the concentration of IL-6, and (F) TNF-α in NRs 
() and SVRs (). P values were calculated using Mann Whitney’s test (*P<0.05; **P<0.01). 




















used to dissolve the inhibitors) in cell culture media was 0.2% and was confirmed to be non-
toxic to cells.  
 
Detection of pSTAT3 levels in mDCs upon IFN-α treatment. mDCs were treated with IFN-α 
for 15 minutes. Immediately after treatment, cells were fixed with BD Cytofix™ buffer for 10 
minutes at 37°C followed by permeabilization with BD™ Phosflow Perm Buffer III for 30 
minutes on ice. Cells were then washed twice in staining buffer (PBS with 2% heat inactivated 
FBS, 0.09% Sodium Azide and 2 mM EDTA) and stained with PE mouse anti-STAT3 (pY705) 
antibody (BD Biosciences) for 30 minutes at room temperature. After staining, cells were 
washed with staining buffer, resuspended in PBS and analyzed on a BD FACSCalibur™ flow 
cytometery instrument. 
 
Evaluation of miR-221-3p targets in mDCs. mDCs were transfected with mirVana miRNA 
miR-221-3p mimic (Ambion) using Lipofectamine RNAiMAX transfection reagent (Life 
Technologies). Briefly, 106 cells were plated in a 6-well cell culture treated plate at a density of 
5x105 cells/ml and transfected with 30 nM of miR-221 mimic (Mature miRNA sequence: 
AGCUACAUUGUCUGCUGGGUUUC, miRBase Accession#MIMAT0000278) or miRNA 
mimic negative control according to the manufacturer’s protocol. cDNA required for qPCR-
based mRNA quantitation was generated using QuantiTect Reverse Transcription kit (Qiagen). 
qPCR was performed using QuantiTect SYBR Green PCR kit (Qiagen). GAPDH was used as 








Th1/Th2/Th17 cytokines secreted by miR-221 mimic transfected mDCs. Culture 
supernatants collected from IFN-treated cells were used to measure the concentration of a panel 
of 12 cytokines (IL2, IL4, IL5, IL6, IL10, IL12, IL13, IL17A, IFN-γ, TNF-α, G-CSF, and  
TGF-β1) using Human Th1/Th2/Th17 Cytokines Multi-Analyte ELISArray Kit (SA Biosciences, 
Qiagen) according to manufacturer’s protocol. Briefly, antigen standards (500 ng/ml) 
corresponding to each of the twelve cytokines were prepared. 50 µ l of assay buffer (supplied 
with the kit) was pipetted into each well (every well has a capture antibody specific to a 
cytokine) followed by addition of 50 µl antigen standards or undiluted culture supernatant in the 
appropriate wells. Plate was gently shaken and incubated for 2 hours at room temperature. After 
2 hours, plates were decanted and washed thrice with the washing buffer (supplied with the kit) 
followed by incubation with biotin-conjugated detection antibodies for 1 hour at room 
temperature and washed thrice thereafter. In the end, cytokines were detected colorimetrically by 
addition of Avidin-HRP solution followed by addition of substrate solution. 
 
Clinical samples. A total of 24 HCV/HIV-1 co-infected, PEG-IFN-α/RBV treatment naïve 
patients were recruited from the Hepatitis Clinic of New York/Weill/Cornell Medical Center in a 
cohort study. The study design was approved by the Institutional Review Board of Weill Medical 
College of Cornell University and conforms to the 1975 Helsinki guidelines for the conduct of 
human research. Inclusion criteria, as described previously, required that patients have detectable 
HCV RNA, be on a stable course of antiretroviral therapy or no antiretroviral agents for at least 
four weeks prior to pegylated-interferon/RBV initiation, and to have a CD4+ T-cell count ≥100 








Figure 4.6: Higher miR-221 expression in total liver cells and kupffer cells of HCV-infected 
individuals compared to individuals with alcoholic cirrhosis (A) Bar graph indicating miR-
221 expression in total liver cells and kupffer cells of HCV-infected individuals as well as 
individuals with alcoholic cirrhosis. (B) Bar graph indicating miR-221 expression in total liver 
cells of HCV-infected individuals and individuals with alcoholic cirrhosis upon 24h IFN-α 
treatment (C) Bar graph indicating miR-221 expression in kupffer cells of HCV-infected 

































opportunistic infections, on active substance abuse, or were pregnant or lactating. Subjects were 
treated with 1.5 µg/kg of PEG-INTRON (Schering Plough, Kenilworth, NJ) once weekly and a 
1000-1200 mg total daily dose of RBV (Rebitrol, Schering Plough), taken every 12 hrs for up to 
48 weeks. Patients with HCV RNA below detection (<29 IU/ml) 24 weeks after treatment  
cessation are SVRs.  
 
Isolation of Kupffer cells from HCV-infected and alcoholic cirrhotic patients. We obtained 
total liver cells from HCV-infected and alcoholic cirrhotic patients from Emory University liver 
transplant center. For isolation of kupffer cells, we first isolated the mononuclear ells using 
percoll density gradient centrifugation. From the mononuclear cells, CD14+ kupffer cells were 
isolated using positive selection with CD14+ positive isolation kit (StemCell) 
 
Statistical Analysis. Data reported in the figures represent the average of at least two 
independent experiments. Statistical significance was determined by Student's t-test or Mann-
Whitney test. Error bars represent the means ± standard deviation (SD). Data were analyzed and 
graphs were generated using Prism 6 (GraphPad Software). 
 
Discussion 
Although a great deal of progress has been made in uncovering the cellular pathways responsible 
for the induction of IFN-I, the underlying mechanisms of action of IFN-I especially in context of 
their immunomodulatory functions are poorly studied. Another noteworthy point is that most 
biological effects of IFNs are attributed to their activation of JAK/STAT pathway that ultimately  
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results in transcriptional activation of Interferon-stimulated genes (ISGs) whose protein products 
possess effector functions associated with IFNs. Emerging evidence, however, strongly suggests 
that IFN-I can function through modulation of cellular miRNAs. Also, several miRNAs have 
been shown to play important roles in controlling the functions of DC, professional antigen 
presenting cells that play a critical role in host immune response to various pathogens. In this 
study, we investigated the IFN-α-miRNA axis in DCs.  
Firstly we identified miR-221-3p to be significantly downregulated in two DC subsets, 
mDCs and pDCs as well as B cells in response to IFN-α (Fig. 4.1). Interestingly, it has been 
recently demonstrated that miR-221 is significantly downregulated upon maturation of 
monocyte-derived DCs using IL-1β, IL-6, TNF-α, and PGE237. IFN-α is also known to promote 
DC maturation38 and therefore it is reasonable to believe that miR-221 downregulation is a 
hallmark of DC maturation. Knock down of miR-221 expression in DCs could thus be an 
important strategy to promote their maturation and hence their ability to prime T cell response in 
response to a pathogen.  
In addition to the JAK-STAT pathway, IFNs can activate several other signaling 
cascades. IFN-I activate a member of the CRK family of adaptor proteins called CRKL, that 
regulates signaling through the C3G/Rap1 pathway39. IFN-I can also activate p38 mitogen-
activated protein kinase and phosphatidylinositol 3-kinase signaling pathway to induce gene 
transcription39. In light of this, we ascertained that IFN-α-induced miR-221 downregulation is 
dependent on activation of JAK/STAT pathway (Fig. 4.2A) and is associated with upregulation 
of STAT1 and STAT4 mRNA levels (Fig. 4.2B). Next, we validated BCL2L11, CDKN1C and 
SOCS1 as miR-221 targets in mDCs (Fig. 4.3A and 4.3B). We also showed that miR-221 
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overexpression leads to increased IL-6 and TNF-α secretion by mDCs. SOCS1 has been 
previously shown to negatively regulate IL-6 and TNF-α levels by inhibiting the JAK/STAT 
pathway40, 41 and our study shows that miR-221 is involved in controlling IL-6 and TNF-α levels 
by knocking down SOCS1. It is worth noting that miR-221 downregulation upon IFN-α 
treatment coincides with increased IL-6 and TNF-α secretion (data not shown); however it is 
difficult to attribute this to IFN-miR-221-SOCS1 axis since IL-6 and TNF-α could be directly 
inducible upon IFN-α signaling as well.  
It is worth noting that IFN-α can have distinct biological outcomes in spite of a common 
proximal signal. This is possible because IFN-α can differentially activate various STAT family  
members (STAT1, 2, 3, 4, 5 and 6) each having distinct target genes and biological functions. 
STAT1, 2 and 3 are most commonly studied STATs. While STAT1 and STAT2 are associated 
with antiviral and proinflammatory response, STAT3 has been shown to balance and restrain the 
pro-inflammatory pathways induced by IFN-α42, 43. Higher pSTAT3 levels, observed in several 
cancers, have been demonstrated to upregulate miR-221 expression35, 36, which promotes 
proliferation of cancer cells44, 45. STAT3 is known to play a critical role in normal DC 
differentiation46. Interestingly, inhibition of Jak2/STAT3 signaling leads to activation of 
immature DCs47. In light of these observations, it is possible that both anti-proliferative and DC 
activation potential of IFN-α are mediated through inhibition of STAT3 and resulting miR-221 
downregulation; however there is no clear consensus on this48, 49. In this study we have shown 
that IFN-α inhibits STAT3, which results in miR-221 downregulation (Fig. 4.4).  
Although the use of IFN/Ribavirin in combination with the newly approved direct-acting 
antiviral agents (DAAs) has improved HCV cure rates, high cost of DAAs along with emergence 
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of drug-resistant HCV variants remain important concerns. Therefore, IFN-α will continue to be 
an important component of treatment and identification of molecular/genetic factors that help 
predict the treatment response will play a key role in better clinical management of HCV 
infection. The importance of IFN in resolving HCV infection is evident by the fact that HCV has 
evolved molecular mechanisms to impair IFN signaling50, 51. We have established that IFN-α 
induces miR-221 downregulation in mDCs. Next, we showed that PBMCs of NRs have lower 
pre-treatment levels of miR-221 compared to SVRs and seronegative controls (Fig. 4.5). This 
leads to an interesting hypothesis that lower miR-221 levels in NRs could be a result of 
constitutive IFN-α signaling. It also corroborates a well-validated fact that hepatocytes of NRs 
have higher pre-treatment levels of ISGs compared to SVRs. Constitutive IFN-α signaling in 
both periphery and liver could thus be the cause of refractoriness of cells to the antiviral and 
immunomodulatory effects of IFN-α. Since our data underscores the role of STAT3 in 
controlling miR-221 expression, it will be interesting to investigate whether lower miR-221 
expression in NRs is a result of lower STAT3 expression/activity. Our study also demonstrated 
that CD54 (miR-221 target) expression on mDCs and IL-6 and TNF-α levels secreted by 
PBMCs in response to in vitro IFN-α/Ribavirin treatment negatively correlate with miR-221 
expression in SVRs and NRs, which highlights the role of miR-221 in controlling DC functions. 
Since liver is the primary site of HCV infection, we investigated miR-221 expression in total 
liver cells as well as kupffer cells, which are major liver-resident antigen presenting cells. miR-
221 expression in total liver cells and kupffer cells was higher in individuals with chronic HCV 
infection as compared to individuals compared to individuals with alcoholic cirrhosis (Fig. 6A). 
Since our study shows that miR-221 overexpression enhances the secretion of pro-inflammatory 
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cytokines IL-6 and TNF-α, higher miR-221 levels in HCV individuals could potentially be the 
cause of inflammation characteristic of chronic HCV infection. Since we could not study miR-
221 regulation in liver resident mDCs (due to difficulty in obtaining enough liver cells) from 
HCV-infected patients during HCV acute and chronic infection, it remains a very crucial future 
endeavor. 
Overall, this study has significant contribution in advancing our understanding of 
molecular mechanisms by which IFN-I exert their immunomodulatory functions. This will 
greatly help us address why IFNs effectively control the development of some 
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Type I IFNs activate intracellular antimicrobial programmes and help shape the innate 
and adaptive immune responses. Canonical type I IFN signaling activates the JAK/STAT 
pathway, leading to transcription of IFN-stimulated genes (ISGs). Importantly, host, 
pathogen and environmental factors have been shown to alter/regulate the responses of 
target cells to this signaling pathway thus playing a decisive role in overall outcome of 
type I IFN signaling. Presence of multiple levels of control on IFN signaling is confirmed 
by the fact that type I IFNs are known to restrain the development of some 
immunopathologies (such as inflammatory bowel disease and multiple sclerosis) while 
increasing the severity of autoimmune diseases (such as psoriasis and systemic lupus 
erythematosus)1-5. One common explanation for these opposing effects of IFNs is 
differential regulation of seven STAT family members in different tissues or organs 
under different physiological and/or inflammatory conditions. It is well established that 
the alliance between type I IFNs and DCs plays a critical role in linking innate and 
adaptive immunity6-9. Although most of the biological effects of type I IFNs are 
attributed to their regulation of protein-coding genes, recent evidence suggests that type I 
IFNs can regulate expression of microRNAs (miRNAs) in various cell types10-17 
including those associated with the innate and adaptive immune system18-20. miRNAs act 
as posttranscriptional regulators of gene expression by binding to and 
degrading/translationally repressing their target mRNAs21. It is becoming increasingly 
evident that miRNAs have profound effects on DC functions such as activation, 
maturation, cytokine secretion and antigen presentation15,22-29.  
miR-155 is one of the most well-studied miRNAs in terms of its role in immune 
system. It is expressed upon activation of B cells, T cells, and macrophages30. Its 
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upregulation also appears to be a hallmark of DC maturation. Increased miR-155 
expression is observed upon maturation of various mouse and human DC subsets in 
response to TLR ligands, TNF-α, and IFN-α31-33. miR-155 has been shown to play an 
important role in optimal functioning of mature DCs, as mature DCs lacking miR-155 fail 
to activate T cells properly34. Another study shows that miR-155–deficient DCs lead to 
impaired CD4+ T cell activation due to reduced expression of MHC II, CD40, and CD86, 
as secretion of IL-12p40, IL-12p35, and TNF-α32. Multiple targets of miR-155 in DCs 
have been identified. One of them is PU.135, a transcription factor known to regulate the 
expression of a number of myeloid genes, including DC-specific C-type lectin DC-SIGN. 
Therefore DC maturation is accompanied by reduced expression of DC-SIGN35. 
Interestingly, DCs are known to bind and transmit HIV-1 to neighboring CD4 T cells36. 
This binding of HIV-1 to DCs is mediated by the interaction between HIV-1 gp120 and 
DC-SIGN. Therefore, reduced expression of DC-SIGN during DC maturation can result 
in reduced transmission of HIV-1 to CD4 T cells. KPC1 is another experimentally 
validated target of miR-15531. KPC1 is known to polyubiquitylate and degrade a pro-
apoptotic protein CDKN1C. Overexpression of miR-155 thus prevents CDKN1C 
degradation in DCs, which leads to their apoptosis31. c-Fos is another direct target of 
miR-155, and upregulation of miR-155 upon DC maturation results in downregulation of 
c-Fos. Transduction of DCs with c-Fos is shown to inhibit their proinflammatory 
cytokine expression as well as T cell activation potential, which mirrors the effect of loss 
of miR-155. This suggests that c-Fos can repress DC maturation, and mir-155 targeting 
of c-Fos allows DCs to mature properly. Both miR-155 and its star-form miR-155* are 
also upregulated upon TLR stimulation of human pDCs33. The two strands were shown to 
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play opposing roles in regulation of IFN-α production by pDCs. At early stages after 
activation miR-155* targeted IRAKM to enhance IFN-α production, whereas at later 
stages miR-155 targeted TAB2 to inhibit the same. This is an interesting example of 
miRNA-mediated fine-tuning of cellular behavior. Both miR-155 and miR-155* are 
formed from the same pre-miRNA transcript but miR-155* degrades at a slower rate 
compared to miR-155. This leads to rapid accumulation of miR-155* which quickly 
facilitates IFN-α production by pDCs (the main function of activated pDCs is to produce 
IFN-α). In order to prevent excess IFN-α production, miR-155, which has slowly 
accumulated to a reasonable level, takes over and suppresses IFN-α production by 
targeting TAB2. miR-155 has been shown to regulate STAT1 expression37,38. miR-155 
overexpression in human hepatocellular carcinoma cells (HepG2, H7402) results in 
suppression of SOCS137. SOCS1 is a known negative regulator of the JAK–STAT 
pathway, and miR-155 overexpressing HepG2 cells have increased STAT1 
phosphorylation which results in upregulation of IFN-inducible genes, MxA and ISG15. 
Additionally, an enhanced anti-HBV effect is observed in HepG2 cells after miR-155 
overexpression37. Interestingly, there exists a positive feedback loop of miR-155 and 
STAT1: miR-155 overexpression upregulates STAT1 phosphorylation and STAT1 in 
turn drives the expression of miR-15538. There are two putative STAT1 binding sites in 
the miR-155 promoter. Electrophoretic mobility shift assay (EMSA) further demonstrates 
binding ability of STAT1 to the miR-155 promoter38. Various studies have investigated 
miR-155 expression in monocytes and PBMCs of HIV-1 and HCV-infected individuals. 
High levels of TNF-α have been reported in serum of chronic HCV infected treatment-
naïve individuals compared to SVRs and seronegative controls39. Consistent with ability 
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of TNF-α to upregulate miR-155, monocytes of chronic HCV infected treatment naïve 
individuals have higher miR-155 expression compared to SVRs and seronegative 
controls. Another study reports that PBMCs from HCV-infected and seronegative 
controls upregulate miR-155 in response to IFN-α suggesting that HCV infection might 
not interfere with IFN signaling in PBMCs40. As expected, stimulation with Imiquimod (a 
TLR7 ligand) upregulates miR-155 in control PBMCs but downregulates miR-155 in 
HCV-infected PBMCs suggesting that HCV can interfere with TLR7 pathway and 
prevent miR-155 upregulation40. miR-155 expression is shown to correlate with the 
extent of HCV replication in PBMCs41. Our data shows that pretreatment expression of 
miR-155 is significantly higher in NRs compared to SVRs. We believe this could be due 
to both TLR mediated sensing of HCV by peripheral immune cells such as monocytes, 
macrophages and DCs as well as by endogenous IFN secreted by pDCs. miR-155 
upregulation is also associated with increased viral load in HIV-1 infected individuals42. 
Collectively, miR-155 upregulation during DC activation is necessary for calibrating the 
expression of multiple genes that operate coordinately to control DC maturation, survival 
and cytokine production. Also, miR-155 expression in PBMCs positively correlates with 
HCV RNA levels (in serum as well as PBMCs) of infected individuals and can be 
predictive of treatment outcome. 
miR-221 belongs to the miR-221/222 cluster on X chromosome. Expression of 
miR-221 is upregulated in several tumors. Interestingly, miR-221 inhibition (using 
antisense miR-221) in U251 glioma cells leads to increased expression of STAT1 and 
STAT2 and upregulation of many ISGs43. These studies provide a solid foundation for 
tumor utilization of miRs to evade the antiproliferative effects of IFNs44. Role of miR-
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221 in DC development and functions is beginning to be explored. Lu et al. 31 recently 
reported that miR-221 is highly upregulated during differentiation of human monocytes 
into immature DCs. miR-221 upregulation during DC differentiation leads to 
downregulation of a known miR-221 target CDKN1C. CDKN1C is a pro-apoptotic 
protein and its downregulation contributes to the survival of immature DCs following 
their differentiation from monocytes31. However, upon DC maturation, miR-221 is 
downregulated leading to accumulation of CDKN1C. It is important to note that miR-155 
is upregulated during DC maturation. Increased miR-155 leads to downregulation of 
KPC1 (protein that is responsible for degrading CDKN1C). Overall, DC maturation leads 
to upregulation of CDKN1C as a direct effect of miR-221 downregulation and an indirect 
effect of miR-155 upregulation. It is worth noting that unlike DCs, CDKN1C is 
downregulated in macrophages in response to mitogenic stimulation45. This suggests a 
specific pathophysiological role of maturation-induced apoptosis in DCs (discussed in 
detail in later sections). miR-221 upregulation has been shown to play an important role 
in tumorigenesis of hepatocellular carcinoma. However, the role of miR-221 in HCV 
infection remains unknown. Recently, Xu et al. showed that miR-221 is upregulated in 
serum of chronic HCV individuals as well as Huh7.5.1 cells infected with HCVcc. The 
authors also showed that miR-221 mimic could enhance anti-HCV effect of IFN-α in 
HCVcc model whereas miR-221 inhibitor had reverse effects. Furthermore, SOCS1 and 
SOCS3, which are known to suppress IFN/JAK/STAT pathway, were identified as the 
targets of miR-221 and were involved in the effect of miR-221. miR-221 expression in 
PBMCs of HIV-1 elite controllers is higher than viremic progressors46, which suggests 
that higher miR-221 expression in infected cells as well as PBMCs could be beneficial in 
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antiviral defense. Our data shows that prior to as well as at week 4 of IFN/RBV 
treatment, PBMCs of NRs had significantly lower expression of miR-221 compared to 
SVRs and seronegative controls. Due to limitation of sample amount, we could not 
profile miR-155 and miR-221 expression in DCs, and therefore miR-155/miR-221 
expression in DCs of NRs and SVRs before and during IFN/RBV treatment remains an 
important area of investigation in terms of HIV-1/HCV immunopathogenesis. 
As discussed above, type I IFNs are capable of inducing a strong antiproliferative 
response in different cell types. This antiproliferative response is a combination of cell 
cycle arrest (particularly S-phase arrest47,48) and initiation of apoptosis49. IFN-induced 
apoptosis is JAK-STAT pathway dependent50, however the identity of JAK-STAT 
pathway-induced pro-apoptotic genes is only beginning to be explored. We show, in 
healthy donors, that IFN-α downregulates miR-221 in mDCs. It has been recently shown 
that miR-221 inhibition can induce apoptosis, via upregulation of its target CDKN1C, in 
DCs31. CDKN1C is an established pro-apoptotic protein and its regulation by miR-221 
has been reported in several cell types, including cancer cells and mast cells as well51-53. 
We also show that miR-221 overexpression can downregulate the expression of pro-
apoptotic genes CAV1, MX1, SHB, TNFSF10 (TRAIL), BCL2L11 as well, some of 
which are already implicated in DC apoptosis54. DC apoptosis plays an essential 
pathophysiological role in controlling tolerance and immunity55. The most compelling 
evidence for the role of DC apoptosis in maintaining self-tolerance is that blocking DC 
apoptosis in mice leads to DC buildup and the development of systemic autoimmune 
diseases56. Consistent with this, individuals with autoimmune lymphoproliferative 
syndrome are characterized by DCs that are defective in undergoing apoptosis57. In 
153
addition, it has been shown that uptake of apoptotic DCs by immature DCs induces them 
to secrete TGF-β, which in turn promotes the differentiation of naive T cells into 
regulatory T cells. Therefore, induction of DC apoptosis may be an important 
physiological role of type I IFNs in immunity. However, it is important to note that DC 
apoptosis during HIV-1 and HCV infection is known to impair the antiviral immune 
response. Therefore during HIV-1 and HCV infection, the pro-apoptotic effect of IFNs 
can further impair the antiviral immune response. 
Pedersen et al have shown that type I IFNs can induce the expression of five 
miRNAs (miR-196, miR-296, miR-351, miR-431 and miR-448) that have sequence-
complementarity with HCV genomic RNA. The introduction of synthetic miRNA-
mimics corresponding to these five miRNAs attenuates HCV replication and infection, 
whereas neutralization of these antiviral miRNAs with anti-miRNAs enhances the same. 
Same study also demonstrated that type I IFNs can downregulate the expression of liver-
specific miR-122, miRNA that is known to HCV genomic RNA, stabilize and hence 
enhance its replication. Both miR-155 and miR-221 have not been predicted to bind to 
HCV genomic RNA suggesting that they may not have direct antiviral effects on HCV.  
Our data also shows that IFN-α-induced miR-221 downregulation is mediated by 
STAT3 inhibition. STAT3 has been shown to negatively regulate DC activation and 
functions58-61 as well as STAT1-dependent induction of inflammatory genes62. 
Orchestration of immune responses by DCs depends on their state of maturation. In 
response to infection, DCs undergo maturation and resulting mature DCs are capable of 
priming the immune response. In the absence of infection, majority of DCs remain in an 
immature state that induces tolerance to self-antigens. Interestingly, IL-6 and IL-10 are 
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known to pre-dominantly activate STAT3 and prevent DC maturation63. Our data shows 
that myeloid DCs in culture constitutively produce IL-6 and IL-10 which could be one of 
the reasons for their higher p-STAT3 levels. It is also possible that mDCs have higher 
constitutive levels of p-STAT3, in fact a recently published study has shown that STAT3 
plays a major role in DC differentiation from pre-cursor cells64. Therefore, it is possible 
that in absence of infection, IL-6 and IL-10 produced by DCs could restrain their 
maturation in a STAT3-dependant manner. In support of this, it has been showed that 
activated STAT3 can attenuate STAT1 activation by IL-6 and IL-10. STAT3 can also 
oppose STAT1 function by inducing the expression of genes such as heme oxygenase-1, 
BCL3, and IL-1 receptor antagonist that have anti-inflammatory functions. In light of 
this, it is quite possible that IFN-α, released abundantly during infection, inhibits STAT3 
in order to lift the activation/maturation block on DCs. In fact our data showed that IFN-
α treatment of mDCs elevated p-STAT1 levels but moderately reduced p-STAT3 levels. 
Recently, many studies have suggested that STAT1 and STAT3 compete to bind to 
phosphorylated IFNAR62,65. This also explains why cells with different ratios of 
STAT1:STAT3 can respond differently to IFNs. Interestingly, some of the STAT3 
molecules are already phosphorylated in mDCs prior to IFN treatment (due to 
constitutively produced IL-6/IL-10), plus it is possible that mDCs have higher STAT1 
levels relative to STAT3. In light of this, it is not unreasonable to believe that higher 
levels of latent STAT1 molecules compared to STAT3 would be able to outcompete 
STAT3 leading to strong STAT1 activation but weak STAT3 activation. The STAT1-
STAT3 competition model explains lack of STAT3 activation by IFN-α in mDCs, 
however it does not explain moderate reduction in IFN-α-induced STAT3 inhibition. 
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Therefore, it is likely that there are other mechanisms by which IFN-α can inhibit 
STAT3. In light of this, various studies have shown that IFN-α can induce negative 
regulators of inflammation (such as SOCS1 and SOCS3), which can suppress IL-6 and 
IL-10-mediated STAT3 activation by inhibiting JAK activity. 
 Higher pSTAT3 levels, observed in several cancers, have been demonstrated to 
upregulate miR-221 expression66,67. Higher miR-221 levels are known to promote rapid 
proliferation and reduced apoptosis of cancer cells68,69. Our data shows that STAT3 
activation, dimerization and DNA-binding ability using BP-1-102 (a chemical inhibitor) 
downregulates miR-221 thus confirming that STAT3 positively regulates miR-221 
expression. Since we have already shown that IFN-α inhibits STAT3, we postulate that 
IFN-α induces miR-221 downregulation by inhibiting STAT3. In order to further validate 
this model, more in-depth studies should be performed. First and foremost, it should be 
confirmed that p-STAT3 binds to the promoter (or any other regulatory region) of miR-
221 gene and drives its expression [using techniques such as chromatin 
immunoprecipitation (ChIP) or electrophoretic mobility shift assay (EMSA)]. Next, it 
should be demonstrated that IFN-α treatment of mDCs abrogates STAT3 binding to miR-
221 gene promoter. Since STAT3 recruited to miR-221 gene promoter could be in the 
form of STAT3-STAT3 homodimer or STAT1-STAT3 heterodimer, its important to 
study whether STAT1 binds to miR-221 gene promoter as well. If both STAT1 and 
STAT3 bind, it is possible that STAT1-STAT3 regulates miR-221 expression but if only 
STAT3 but not STAT1 binds, it is possible that STAT3-STAT3 homodimer regulates 
miR-221 expression. On the other hand, if STAT1 but not STAT3 binds to miR-221, it 
would mean that STAT1-STAT2-IRF9 complex (ISGF3) could possibly be regulating 
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miR-221 expression. Involvement of ISGF3 in miR-221 regulation can be determined by 
investigating whether STAT2 binds to miR-221 gene promoter. There are studies that 
show that serine phosphorylation of STATs can affect their DNA-binding ability and thus 
their transcriptional activity70. Therefore, it is important to note that reduced binding (in 
chIP or EMSA experiments) can be a result of reduced phosphorylation and/or 
dimerization and/or reduced DNA binding ability of STAT3. Since we have already 
shown that IFN-α inhibits STAT3 phosphorylation, subsequent studies should study 
whether IFN-α can negatively regulate STAT3 dimerization and DNA-binding ability. 
An alternative way to validate the involvement of STAT3 in regulating miR-221 
expression is the use of RNA interference approaches (shRNA/siRNAs against STAT3) 
to knock down the expression of STAT3. STAT3 knockdown should reduce miR-221 
expression, plus IFN-α treatment of STAT3 knockdown mDCs should significantly 
reduce the magnitude (if not completely prevent) of miR-221 downregulation. 
Performing similar experiments using shRNA/siRNAs against STAT1 will help 
determine whether STAT1-STAT3 heterodimer or STAT3-STAT3 homodimer is 
responsible for regulating miR-221 expression. Since efficiency of RNA interference-
based knockdown is not 100%, use of STAT1 knockout mice (instead of using RNAi to 
knockdown STAT1) may be a good strategy to ascertain the involvement of STAT1 in 
regulating miR-221 expression. Since STAT3 deficiency in mice is embryonically 
lethal71. STAT3 knockout in the bone marrow and endothelial cells, under the control 
results in development of Crohn's disease-like phenotype in mice. Therefore, other 
alternative strategies should be developed to understand the role of STAT3 in miR-221 
regulation. Use of recently developed technology that utilizes a class of engineered DNA-
157
binding proteins called zinc finger nucleases (ZFNs) to facilitate targeted editing of the 
genome by creating double-strand breaks in DNA can be a very useful strategy to create 
STAT1/STAT3 knockout human mDCs and study the role of STAT1/STAT3 in miR-221 
regulation. Another possibility is that IFN-α indirectly downregulates miR-221 through 
STAT1/STAT3-induced upregulation of transcription activators of miR-221 
transcription, or through STAT1/STAT3-induced downregulation of transcriptional 
repressors of miR-221. In order to address whether STAT1/STAT3 induced translation of 
transcriptional activators/repressors is responsible for regulating miR-221 expression, 
mDCs can be treated with protein synthesis inhibitors like cycloheximide followed by 
treatment with IFN-α. If translation of new proteins is necessary for IFN-α-induced miR-
221 downregulation, then inhibition of protein synthesis prior to IFN-α will not result in 
miR-221 downregulation. Also, since some of the miR-221 targets such as CDKN1C and 
SOCS1 can be directly induced in response to IFN-α, it should be confirmed whether 
their upregulation is a direct effect of IFN-α or an indirect effect mediated through 
downregulation of miR-221. This needs an experiment in which mDCs are transfected 
with miR-221 mimic prior to IFN-α treatment. If it is an indirect effect mediated through 
miR-221 downregulation, then miR-221 overexpression prior to IFN-α will prevent the 
upregulation of CDKN1C and SOCS1. 
It is estimated that nearly 3% of the world population are chronically infected 
with HCV. With the advent of anti-HCV drugs (DAAs), we have made huge strides in 
HCV treatment, but high cost of DAAs and drug-resistance remain important concerns. 
Therefore, IFN-α will continue to be an important component of treatment and 
identification of molecular/genetic factors that help predict the treatment response will 
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play a key role in better clinical management of HCV infection. Our study has significant 
contribution in advancing the understanding of molecular mechanisms by which IFN-I 
exert their immunomodulatory functions. This will greatly help us address why IFNs 
effectively control the development of some immunopathologies while exacerbating the 
severity of others.  
Miravirsen (antisense of miR-122) is the first miRNA-based drug that has shown 
great promise in the treatment of chronic HCV infection. Other studies have also 
demonstrated the anti-HCV effects of miR-196, miR-296, miR-351, miR-431 and miR-
448 mimics known to directly bind HCV RNA and suppress its replication. Our study 
shows that besides direct effects on HCV, miRNAs such as miR-155 and miR-221 can 
control anti-HCV immune response and hence contribute to HCV immunopathogenesis. 
We live in the age of personalized medicine. In future, it remains to be seen whether we 
could harness the functions of miR-155 and/or miR-221 to potentiate our immune system 
against HCV. Development of multi-pronged strategies, which precisely target HCV at 
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